It has been about a month since the last earnings report for Chemours (CC - Free Report) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Chemours due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Chemours' Q2 Earnings & Revenues Lag Estimates on Lower VolumesChemours reported a net loss of $274 million or a loss of $1.81 per share for the second quarter of 2026. This compares favorably with the year-ago quarter’s net loss of $380 million or a loss of $2.53 per share.
Barring one-time items, earnings were 42 cents per share, which missed the Zacks Consensus Estimate of 43 cents by roughly 2.3%. Adjusted earnings also declined from 61 cents per share in the year-ago quarter.
The company reported second-quarter net sales of $1,591 million, reflecting a 1% decrease from the previous-year quarter. The figure missed the Zacks Consensus Estimate of $1,674.1 million by roughly 5%. Net sales were affected by a 4% decrease in volumes, partly offset by a 2% increase in price and a 1% favorable currency impact.
Adjusted EBITDA declined 5% year over year to $247 million for the quarter from $260 million. The decrease was due to higher costs in APM associated with the Washington Works outage and lower sales following the SPS Capstone line closure, partly offset by pricing increases across all segments.
Segment HighlightsThe TT division recorded revenues of $661 million in the second quarter, marking a 1% increase from the previous year. The figure missed our estimate of $663.6 million. The year-over-year increase was driven by a 2% rise in global pricing and a 1% currency tailwind, which more than offset a 2% decline in global volumes.
In the TSS segment, revenues decreased 1% year over year to $591 million in the reported quarter. The figure missed our estimate of $637.3 million. The decline was due to a 4% fall in volumes, partly offset by a 2% increase in price and a slight currency tailwind. Lower volumes primarily reflected weaker North American stationary AC aftermarket sales of Opteon blends compared with elevated demand in the prior-year quarter.
TSS adjusted EBITDA increased 3% year over year to $213 million, while adjusted EBITDA margin improved one percentage point to 36%, aided by higher pricing and the timing of certain costs.
Revenues in the APM unit amounted to $326 million, which declined 6% year over year. The figure missed our estimate of $338.2 million. The downside was mainly caused by a 9% decrease in volumes, partly offset by a 2% increase in price and a slight currency tailwind. The volume decline primarily reflected the SPS Capstone line closure, while Performance Solutions sales rose 8% year over year on strength in data center and semiconductor end markets.
FinancialsOperating cash flow in the second quarter was $158 million compared with $93 million in the year-ago quarter. Capital expenditures were $44 million compared with $43 million in the prior-year quarter. Free cash flow increased to $114 million from $50 million a year earlier.
As of June 30, 2026, Chemours had consolidated gross debt of $3.9 billion. Debt, net of $671 million in unrestricted cash and cash equivalents, was $3.2 billion. Total liquidity was $1.6 billion, and the net leverage ratio was approximately 4.4.
OutlookFor the third quarter, the company expects consolidated net sales to decline in the range of 5% to flat sequentially. Consolidated adjusted EBITDA is expected to be in the range of $175-$205 million. Corporate expenses are expected to be $40-$45 million. The company also expects capital expenditures of around $65 million and free cash flow of at least $50 million.
Chemours expects TSS’ net sales to decrease sequentially in the mid-teens to 20% range in the third quarter, reflecting less favorable seasonality and weaker Opteon blends aftermarket demand. Adjusted EBITDA is projected to be between $125 million and $140 million.
TT’s net sales are expected to increase sequentially in the low-to-mid-single-digit percentage range, driven by recent pricing announcements, with stable volumes. Adjusted EBITDA is expected to be in the range of $70-$80 million.
APM’s net sales are expected to increase sequentially in the mid-to-high-single-digit percentage range, driven by normalized operations at Washington Works and continued strength in Performance Solutions. Adjusted EBITDA for APM is expected to be between $20 million and $30 million.
For 2026, Chemours expects net sales to grow in the range of 1-5% year over year and adjusted EBITDA of $775-$825 million. Capital expenditures are expected in the range of $250-$280 million, with free cash flow conversion above 25%. The company continues to target a net leverage ratio of around 3.8x by year-end 2026.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -46.39% due to these changes.
VGM ScoresCurrently, Chemours has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of A on the value side, putting it in the top quintile for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Chemours has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerChemours belongs to the Zacks Chemical - Diversified industry. Another stock from the same industry, Air Products and Chemicals (APD - Free Report) , has gained 4.9% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Air Products and Chemicals reported revenues of $3.16 billion in the last reported quarter, representing a year-over-year change of +4.6%. EPS of $3.47 for the same period compares with $3.09 a year ago.
Air Products and Chemicals is expected to post earnings of $3.60 per share for the current quarter, representing a year-over-year change of +6.2%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.4%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Air Products and Chemicals. Also, the stock has a VGM Score of D.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company ("Chemours" or the "Company") (NYSE: CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Chemours and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year."
On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 10, 2026.
Then, on August 11, 2026, AECOM reported weaker-than-expected results for the third quarter of 2026, which were impacted by a $337 million pre-tax loss related to the delayed completion of a construction management project.
On this news, AECOM's stock price fell $6.25 per share, or 8.53%, to close at $67.05 per share on August 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Chemours and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”
On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 10, 2026.
Then, on August 11, 2026, AECOM reported weaker-than-expected results for the third quarter of 2026, which were impacted by a $337 million pre-tax loss related to the delayed completion of a construction management project.
On this news, AECOM’s stock price fell $6.25 per share, or 8.53%, to close at $67.05 per share on August 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
BlackRock Inc. acquired a new position in shares of The Chemours Company (NYSE:CC – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,283,074 shares of the specialty chemicals company’s stock, valued at approximately $477,769,000. BlackRock Inc. owned about 15.48% of Chemours as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in Chemours during the 1st quarter worth $3,745,000. Old West Investment Management LLC bought a new stake in shares of Chemours in the second quarter valued at about $7,152,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Chemours in the second quarter valued at about $1,467,000. Versor Investments LP acquired a new position in shares of Chemours in the fourth quarter valued at about $314,000. Finally, Penn Capital Management Company LLC increased its position in Chemours by 113.0% during the fourth quarter. Penn Capital Management Company LLC now owns 1,386,819 shares of the specialty chemicals company’s stock worth $16,366,000 after acquiring an additional 735,668 shares during the period. Institutional investors own 76.26% of the company’s stock.
Analyst Upgrades and Downgrades CC has been the subject of a number of recent research reports. JPMorgan Chase & Co. cut their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 13th. Zacks Research cut shares of Chemours from a “strong-buy” rating to a “strong sell” rating in a report on Tuesday, August 11th. Truist Financial dropped their price target on shares of Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Royal Bank Of Canada cut their price target on Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $17.00 price target on shares of Chemours in a research report on Thursday, August 13th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Chemours presently has an average rating of “Hold” and an average target price of $20.10.
Check Out Our Latest Research Report on CC Chemours Price Performance Shares of NYSE:CC opened at $15.40 on Tuesday. The firm has a 50 day moving average of $17.87 and a 200-day moving average of $20.04. The Chemours Company has a 12 month low of $10.44 and a 12 month high of $28.67. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The stock has a market capitalization of $2.32 billion, a PE ratio of -8.06 and a beta of 1.43.
Chemours (NYSE:CC – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the prior year, the business posted ($2.54) EPS. The business’s revenue was down 1.5% on a year-over-year basis. On average, equities research analysts predict that The Chemours Company will post 0.87 EPS for the current fiscal year.
Chemours Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 14th. Chemours’s dividend payout ratio (DPR) is currently -18.32%.
Insider Activity In other Chemours news, CEO Denise Dignam purchased 3,378 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were bought at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the purchase, the chief executive officer owned 339,916 shares in the company, valued at approximately $5,081,744.20. This trade represents a 1.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of the stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the acquisition, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 8,663 shares of company stock worth $130,601. Insiders own 0.85% of the company’s stock.
Chemours Profile (Free Report)
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours’ principal business activities are organized into three core segments.
Further Reading Five stocks we like better than Chemours Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC – Free Report).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
, /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (TSS), Titanium Technologies (TT), and Advanced Performance Materials (APM), today announced the release of its 2025 Sustainability Report.
Chemours releases its 2025 Sustainability Report, showcasing significant progress toward its Corporate Responsibility Commitment goals. "Our sustainability strategy is delivering tangible results while creating long-term value for the company and its stakeholders," said Kathy O'Keefe, Chemours Chief Sustainability Officer. "The progress reflected in this year's report demonstrates how responsible manufacturing, operational excellence, and innovation can work together to reduce our environmental footprint, strengthen our business, and help our customers meet their own sustainability goals. While important work remains, the progress highlighted in this report reflects the dedication of our teams and our commitment to turn ambition into action by delivering solutions that support our customers, communities, and other stakeholders."
The 2025 report highlights progress across responsible manufacturing, climate action, safety, supply chain engagement, and community investment while showcasing how the company is using science, technology, and continuous improvement to advance its sustainability priorities.
2025 Sustainability Progress Highlights:
Achieved an 80% reduction in air and water process emissions of fluorinated organic chemicals (FOCs) since 2018, on track toward the company's goal of reducing FOC process emissions by 99% or more by 2030. Reduced Scope 1 and 2 greenhouse gas (GHG) emissions by 57% since 2018, advancing toward the company's target of a 60% reduction by 2030. Reduced absolute Scope 3 greenhouse gas (GHG) emissions by 30% since 2018, supported in part by increased adoption of Opteon™ low global warming potential (GWP) refrigerants. Recorded zero Tier 1 process safety events and zero distribution safety incidents in 2025 and launched our new "We Strive for Zero" safety aspiration, establishing a clearer, enterprise-wide vision for safety performance. Beyond these results, the report highlights how Chemours is applying chemistry, innovation, and collaboration to help address complex challenges for customers, communities, and society, including:
Advancing emissions detection, measurement, and abatement technologies that support one of the world's most ambitious fluorinated organic compound reduction goals while helping drive broader progress across industry. Helping customers reduce emissions and support the growing demands of AI infrastructure through advanced cooling technologies, including Opteon™ low GWP refrigerants for chillers and two-phase liquid cooling solutions designed to improve energy efficiency and reduce water use. To read the full 2025 Sustainability Report, visit https://www.chemours.com/en/sustainability.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, our progress against our Corporate Responsibility Commitment goals and our expected impact on societal goals, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, and changes in environmental regulations in the U.S. or other jurisdictions could either make it more difficult to comply with environmental regulations or that affect demand for or adoption of our products, have affected or may affect our business and operations and may or may continue to hinder our ability to comply with environmental regulations or provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Chemours and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”
On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 10, 2026.
Then, on August 11, 2026, AECOM reported weaker-than-expected results for the third quarter of 2026, which were impacted by a $337 million pre-tax loss related to the delayed completion of a construction management project.
On this news, AECOM’s stock price fell $6.25 per share, or 8.53%, to close at $67.05 per share on August 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
RALEIGH, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- This week, the Honorable James C. Dever III of the United States District Court for the Eastern District of North Carolina granted plaintiffs’ motion for partial summary judgment for trespass liability in Brent Nix, et al. v. The Chemours Company FC, LLC, et al. The ruling allows the certified class of more than 180,000 North Carolinians to move one step closer to holding the chemical company accountable for decades of exposure to toxic “forever chemicals” in their drinking water. A jury trial is scheduled for March 4, 2027.
“We are very pleased with the court’s decision in granting our clients’ motion for partial summary judgment on trespass liability, as thousands of properties have been impacted by Chemours’ negligence,” said Ted Leopold of Cohen Milstein and Steve Morrissey of Susman Godfrey, who are court-appointed Co-Lead Class Counsel for the certified class in this massive toxic tort litigation. “We look forward to presenting our case to a jury and helping residents along the Cape Fear River achieve the full measure of justice they deserve.”
Plaintiffs allege that since 1980, Chemours and its predecessor, E.I. du Pont de Nemours & Company, illegally discharged toxic PFAS and GenX chemicals, also known as “forever chemicals,” from its Fayetteville Works Plant into the Cape Fear River, impacting the drinking water and homes of more than 180,000 North Carolinians. In particular, plaintiffs contend that water utilities in New Hanover, Bladen, Brunswick, Cumberland, and Pender Counties were contaminated, as were more than 10,000 private wells in the area.
In its ruling, the court held that plaintiffs were entitled to judgment in their favor on their claims of trespass liability. Specifically, plaintiffs contend that chemicals from defendants’ Fayetteville Works plant contaminated drinking water provided to class members via the aforementioned public water utilities and private wells, thereby constituting intentional trespass. Under North Carolina law trespass is defined as the “wrongful invasion of the possession of another.” In this case, the claim of trespass to the real property in question included unauthorized entry by the defendants and damage to the plaintiffs while in possession of the property when the trespass occurred.
On October 4, 2023, the Eastern District of North Carolina certified a class of North Carolina residents whose homes were impacted by the contaminated water, and on November 17, 2023, in a one page order, the United States Court of Appeals for the Fourth Circuit denied DuPont’s and Chemours’ petition to review the order granting class certification.
The class action, Brent Nix, et al. v. The Chemours Company FC, LLC, et al., Case No. 7:17-CV-00189, U.S. District Court, Eastern District of North Carolina, was first filed in 2017.
About Cohen Milstein Sellers & Toll LLP
Cohen Milstein Sellers & Toll LLP is a premier U.S. plaintiffs’ law firm, handling high-profile and often precedent-setting litigation, including environmental toxic tort litigation. With over 100 attorneys across the country, Cohen Milstein has offices in Boston, MA, Chicago, IL, Minneapolis, MN, New York, NY, Palm Beach Gardens, FL, Philadelphia, PA, Raleigh, NC, and Washington, DC. For additional information please visit www.cohenmilstein.com or call (202) 408-4600.
About Susman Godfrey L.L.P.
Susman Godfrey is a nationwide law firm of 150 trial lawyers. It handles high-stakes litigation in a broad range of practice areas and industries, for both plaintiffs and defendants. With a relentless focus on winning at trial, Susman Godfrey has been ranked by Vault as the #1 litigation boutique in America for 12 consecutive years. Visit www.susmangodfrey.com to learn more about our unique approach to winning cases.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company ("Chemours" or the "Company") (NYSE: CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Chemours and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year."
On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 10, 2026.
Then, on August 11, 2026, AECOM reported weaker-than-expected results for the third quarter of 2026, which were impacted by a $337 million pre-tax loss related to the delayed completion of a construction management project.
On this news, AECOM's stock price fell $6.25 per share, or 8.53%, to close at $67.05 per share on August 11, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Key Takeaways Chemours launched Opteon ZE and 515B for stationary chillers serving AI-driven data-center cooling needs.Opteon ZE and 515B offer low GWP and are classified as ASHRAE A2L and A1 refrigerants, respectively.Chemours sees growth opportunities as cooling demand rises and regulatory standards become stricter. The Chemours Company (CC - Free Report) has launched Opteon ZE (R-1234ze(E)) and Opteon 515B (R-515B) for stationary chiller applications, targeting the growing cooling requirements of AI-driven data center infrastructure. The new products expand Chemours’ portfolio of low-global-warming-potential (GWP) refrigerants and strengthen its positioning in cooling markets.
The launch is particularly significant as artificial intelligence is increasing demand for efficient and reliable data-center cooling infrastructure. Chemours is therefore leveraging its Opteon platform to address emerging cooling requirements while supporting customers’ environmental sustainability and decarbonization objectives.
The company has been expanding its presence in data-center cooling, including Opteon ZE and Opteon 515B. These refrigerants are characterized by low GWP and classified as ASHRAE A2L and A1, respectively. It complements the existing portfolio of Opteon refrigerants used in air conditioning, refrigeration, heat pumps and across the HVACR industry.
The company also benefits from its expertise in fluorochemicals. Overall, the intellectual property portfolio Chemours is building could provide additional opportunities for growth as regulatory standards get stricter and an increasing number of data centers drive demand for advanced cooling technologies.
CC’s shares have gained 4.4% over the past year compared with the industry’s 5% rise.
Image Source: Zacks Investment Research
CC’s Zacks Rank & Key PicksCC currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. (NOPMF - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avient Corporation (AVNT - Free Report) .
While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pinned at $1.48 per share, indicating a 202.04% year-over-year increase. NOPMF’sshares have gained 113.6% over the past year.
The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.17 per share, indicating a 12.41% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 30.1% over the past year.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN THE CHEMOURS COMPANY (CC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by emai.
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHEMOURS COMPANY (CC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Chemours should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Birkenstock (BIRK) shares surged following the release of its Q3 results for June, showing a 13% year-over-year revenue increase to â¬719.5 million. Although t
Key Takeaways Chemours cut its Q2 net loss to $274 million, while adjusted EPS fell short of estimates. Sales fell 1% as a 4% volume decline offset higher pricing and favorable currency impacts. Chemours expects Q3 EBITDA of $175-$205 million and 2026 sales growth of 1-5%. The Chemours Company (CC - Free Report) reported a net loss of $274 million or a loss of $1.81 per share for the second quarter of 2026. This compares favorably with the year-ago quarter’s net loss of $380 million or a loss of $2.53 per share.
Barring one-time items, earnings were 42 cents per share, which missed the Zacks Consensus Estimate of 43 cents by roughly 2.3%. Adjusted earnings also declined from 61 cents per share in the year-ago quarter.
The company reported second-quarter net sales of $1,591 million, reflecting a 1% decrease from the previous-year quarter. The figure missed the Zacks Consensus Estimate of $1,674.1 million by roughly 5%. Net sales were affected by a 4% decrease in volumes, partly offset by a 2% increase in price and a 1% favorable currency impact.
Adjusted EBITDA declined 5% year over year to $247 million for the quarter from $260 million. The decrease was due to higher costs in Advanced Performance Materials (APM) associated with the Washington Works outage and lower sales following the SPS Capstone line closure, partly offset by pricing increases across all segments.
The Chemours Company Price, Consensus and EPS SurpriseCC’s Segment HighlightsThe Titanium Technologies (TT) division recorded revenues of $661 million in the second quarter, marking a 1% increase from the previous year. The figure missed our estimate of $663.6 million. The year-over-year increase was driven by a 2% rise in global pricing and a 1% currency tailwind, which more than offset a 2% decline in global volumes.
In the Thermal & Specialized Solutions (TSS) segment, revenues decreased 1% year over year to $591 million in the reported quarter. The figure missed our estimate of $637.3 million. The decline was due to a 4% fall in volumes, partly offset by a 2% increase in price and a slight currency tailwind. Lower volumes primarily reflected weaker North American stationary AC aftermarket sales of Opteon blends compared with elevated demand in the prior-year quarter.
TSS adjusted EBITDA increased 3% year over year to $213 million, while adjusted EBITDA margin improved one percentage point to 36%, aided by higher pricing and the timing of certain costs.
Revenues in the APM unit amounted to $326 million, which declined 6% year over year. The figure missed our estimate of $338.2 million. The downside was mainly caused by a 9% decrease in volumes, partly offset by a 2% increase in price and a slight currency tailwind. The volume decline primarily reflected the SPS Capstone line closure, while Performance Solutions sales rose 8% year over year on strength in data center and semiconductor end markets.
CC’s FinancialsOperating cash flow in the second quarter was $158 million compared with $93 million in the year-ago quarter. Capital expenditures were $44 million compared with $43 million in the prior-year quarter. Free cash flow increased to $114 million from $50 million a year earlier.
As of June 30, 2026, Chemours had consolidated gross debt of $3.9 billion. Debt, net of $671 million in unrestricted cash and cash equivalents, was $3.2 billion. Total liquidity was $1.6 billion, and the net leverage ratio was approximately 4.4.
CC’s OutlookFor the third quarter, the company expects consolidated net sales to decline in the range of 5% to flat sequentially. Consolidated adjusted EBITDA is expected to be in the range of $175-$205 million. Corporate expenses are expected to be $40-$45 million. The company also expects capital expenditures of around $65 million and free cash flow of at least $50 million.
Chemours expects TSS’ net sales to decrease sequentially in the mid-teens to 20% range in the third quarter, reflecting less favorable seasonality and weaker Opteon blends aftermarket demand. Adjusted EBITDA is projected to be between $125 million and $140 million.
TT’s net sales are expected to increase sequentially in the low-to-mid-single-digit percentage range, driven by recent pricing announcements, with stable volumes. Adjusted EBITDA is expected to be in the range of $70-$80 million.
APM’s net sales are expected to increase sequentially in the mid-to-high-single-digit percentage range, driven by normalized operations at Washington Works and continued strength in Performance Solutions. Adjusted EBITDA for APM is expected to be between $20 million and $30 million.
For 2026, Chemours expects net sales to grow in the range of 1-5% year over year and adjusted EBITDA of $775-$825 million. Capital expenditures are expected in the range of $250-$280 million, with free cash flow conversion above 25%. The company continues to target a net leverage ratio of around 3.8x by year-end 2026.
CC’s Price PerformanceChemours’ shares have gained 17.4% in the past year compared with the 6.8% rise of the industry.
Image Source: Zacks Investment Research
CC’s Zacks Rank & Key PicksCC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks are Almonty Industries Inc. (ALM - Free Report) , ClearSign Technologies Corporation (CLIR - Free Report) and Applied Industrial Technologies, Inc. (AIT - Free Report) .
Almonty is expected to report second-quarter results on Aug. 13. The Zacks Consensus Estimate for ALM’s second-quarter earnings is pegged at 10 cents per share. It carries a Zacks Rank #2 (Buy) at present.
ClearSign is scheduled to report second-quarter 2026 results on Aug. 19. The consensus estimate for CLIR’s loss per share is pegged at 25 cents. CLIR presently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Applied Industrial is scheduled to report fourth-quarter fiscal 2026 results on Aug. 13. The Zacks Consensus Estimate for AIT’s fourth-quarter earnings per share is pegged at $2.92. AIT carries a Zacks Rank #2 at present.
New additions to the Opteon™ portfolio support high-performance, sustainable cooling solutions in stationary chillers for AI-driven data centers, and commercial HVAC applications
, /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company, today announced the launch of Opteon™ ZE (R-1234ze(E)) and Opteon™ 515B (R-515B) for stationary chiller applications. The products further expand the industry-leading Opteon™ portfolio and provide customers with additional low-global warming potential (GWP) refrigerant options for large-scale cooling applications, including rapidly growing AI and data center infrastructure.
"AI is reshaping the demands placed on cooling infrastructure, and customers need solutions that can keep pace without compromising efficiency, reliability, or long-term regulatory readiness," said Joseph Martinko, President, Thermal & Specialized Solutions at Chemours. "With Opteon™ ZE and Opteon™ 515B, Chemours is expanding the choices available to chiller OEMs and operators as they build and maintain the critical systems powering data centers, commercial buildings, and other mission critical environments, while further strengthening our position in attractive, high-growth cooling applications."
As demand for artificial intelligence (AI), cloud computing, and digital infrastructure continues to grow, data center operators face increasing cooling requirements, higher heat loads, strict uptime requirements, and the need for solutions that can scale with future growth. Opteon™ ZE and Opteon™ 515B are low-GWP refrigerants designed to help address these challenges with efficient heat removal, reliable performance, and scalability, while supporting decarbonization and climate goals.
The products also support Chemours' continued focus on higher-value applications, including data center infrastructure, where long-term demand trends are driving increased investment in cooling solutions.
Opteon™ ZE (R-1234ze(E)) is a hydrofluoroolefin (HFO) based refrigerant engineered to deliver exceptional performance, characterized by an ultra-low GWP of approximately 1 (AR5), and zero ozone depletion potential (ODP). It has an ASHRAE A2L classification (mildly flammable). It is well suited for air- and water-cooled chillers, commercial air conditioning, heat pumps, and data center cooling applications. Opteon™ ZE offers high energy efficiency and compatibility with commonly used polyolester oil (POE) lubricants.
Opteon™ 515B (R-515B) is a zero ODP refrigerant blend consisting of approximately 91.1% R-1234ze(E) and 8.9% R-227ea. Featuring a GWP of approximately 293 (AR4) and an ASHRAE A1 classification (no flame propagation). For conventional chiller applications, Opteon™ 515B offers a balance of lower GWP, performance, and ease of adoption for customers transitioning from higher-GWP refrigerants.
Together, these products strengthen Chemours' position as a leading provider of low-GWP refrigerant solutions, expanding the company's ability to support a broader range of chiller applications while complementing its existing portfolio of Opteon™ refrigerants used in air conditioning, refrigeration, heat pumps, and across the HVACR industry.
Importantly, Chemours is uniquely positioned to supply these products through its extensive fluorochemicals expertise, and intellectual property portfolio. The company is confident in its ability to manufacture and sell Opteon™ ZE and Opteon™ 515B while respecting applicable intellectual property rights and supporting customers with dependable long-term supply.
Opteon™ ZE and Opteon™ 515B are available now in strategic countries, with additional market availability expected to follow aligned with market demand.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, new product development of refrigerants for chiller applications, expected contributions to advancing data center energy efficiency, improving sustainability, circularity, decreasing environmental footprint, plans to continue investment in research and development, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, market adoption of technologies, geopolitical conditions and global health events, and changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
Corporate leadership is evolving as more women assume top executive roles at publicly traded companies. This transition is increasingly backed by strong business performance, with many women-led organizations delivering innovation, operational excellence and consistent shareholder value across diverse industries. Far beyond a shift in representation, these leaders are driving disciplined execution, prudent capital allocation and long-term strategic growth, helping their companies strengthen competitive positioning and build more resilient, sustainable business models.
The latest reports paint a nuanced picture: women are becoming a structural force in U.S. entrepreneurship, even as funding and systemic gaps persist. One of the clearest takeaways is scale. Women now own more than 40% of all U.S. businesses, employing roughly 12.6 million people and generating $2.8 trillion in revenues. Growth has also been faster than that of male-owned firms, with women-owned businesses expanding nearly twice as quickly between 2022 and 2025. This shift signals that female entrepreneurship is no longer niche—it is central to the U.S. small- and mid-sized business ecosystem, particularly in services, consumer, healthcare and increasingly tech-enabled sectors. The data suggests women are not just starting companies, but building durable, employment-generating enterprises, a key driver of long-term economic resilience.
Female founders are increasingly gaining traction in AI and next-generation technology markets, which have become the primary destinations for venture capital. This indicates a shift from traditional sectors into high-value, innovation-driven markets, positioning women at the center of future growth themes. According to PitchBook's 2025 Female Founders report, U.S. female-founded startups raised a record $73.6 billion in venture capital in 2025, representing 27.7% of total U.S. VC deal value, the highest share on record. Importantly, AI accounted for roughly two-thirds of all venture dollars invested in female-founded startups.
At the same time, capital is becoming more concentrated in fewer, larger deals—often in AI—suggesting that while top-tier female-led companies are scaling rapidly, broader participation remains uneven.
Despite strong progress, a significant funding gap continues to limit the full potential of female founders. All-female founding teams still receive only about 1–2% of total U.S. venture capital, even though evidence suggests they often deliver higher capital efficiency and competitive returns. This imbalance highlights a structural constraint within the venture ecosystem, where access to early-stage and growth funding remains uneven. As a result, many promising female-led startups may struggle to scale at the same pace as their peers, underscoring a sizable untapped opportunity for investors willing to address this gap.
Despite funding challenges, women-led companies continue to drive innovation and resilience, making them attractive investment opportunities. If you want to capitalize on it, our Women Run Companies Screen will help you spot high-potential stocks in this space.
Investors looking to capitalize on opportunities across diverse industries should consider Centene Corporation (CNC - Free Report) in managed healthcare, Darling Ingredients Inc. (DAR - Free Report) in sustainable ingredients and bio-nutrients, General Dynamics Corporation (GD - Free Report) in aerospace and defense, FuelCell Energy, Inc. (FCEL - Free Report) in clean energy and fuel cell technology, and The Chemours Company (CC - Free Report) in specialty chemicals. These companies demonstrate strong leadership and strategic vision within their respective industries, positioning them for long-term growth and value creation.
Ready to uncover more transformative thematic investment ideas? Explore 39 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.
Centene: Sarah M. London has led Centene through one of the most significant strategic transformations in its history since becoming chief executive officer in 2022. Her leadership has focused on restoring profitability following elevated medical costs, strengthening underwriting discipline and improving execution across Medicaid, Medicare and Marketplace businesses. London has emphasized data-driven care management, pricing discipline and enterprise-wide cost optimization while reshaping the leadership structure to accelerate decision-making. These initiatives have positioned Centene to improve operating performance despite regulatory changes and shifting enrollment trends in government-sponsored healthcare programs.
The benefits of this strategy became increasingly evident in the company's second-quarter 2026 results. Total revenues increased 9.9% year over year to $53.6 billion, while adjusted earnings per share (EPS) reached $2.51, significantly exceeding expectations. The health benefits ratio improved to 89.6% from 93.0% a year earlier, reflecting better pricing, stronger medical cost management and improving profitability across key businesses. Centene also generated $3.6 billion in operating cash flow during the quarter and raised its full-year 2026 outlook, including revenue guidance of $193.5-$197.5 billion and adjusted EPS guidance to greater than $4.80, underscoring management's growing confidence in the earnings recovery.
London's most important contribution has been restoring investor confidence through disciplined execution rather than aggressive expansion. Although total at-risk membership declined to 25.9 million, reflecting industry-wide Medicaid and Marketplace normalization, Centene has prioritized higher-quality earnings, margin recovery and capital efficiency over enrollment growth. With stronger medical cost controls, improved balance-sheet flexibility and a renewed focus on operational excellence, London has repositioned Centene for more sustainable long-term earnings growth while navigating an increasingly complex regulatory environment. Currently, Centene sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Darling: Sandra Dudley has played an increasingly important role in Darling’s strategic transformation since joining the company in 2015 as vice president of Strategic Planning & Business Development. She subsequently served as senior vice president of Renewables and Strategy, and later as executive vice president of Renewables and U.S. Specialty Operations. In February 2025, she was appointed executive vice president, chief strategy officer, M&A and AI, expanding her responsibilities to include corporate strategy, mergers and acquisitions, and artificial intelligence initiatives. In this role, she helps shape Darling's long-term growth strategy by identifying value-accretive acquisitions, optimizing the business portfolio and leveraging AI to enhance operational efficiency.
Dudley's expanded role aligns with Darling's focus on disciplined capital allocation and operational optimization. Her strategic oversight supports the company's transition toward higher-value specialty ingredients while improving returns from its global rendering and renewable fuels businesses. In the second quarter of 2026, Darling reported net sales of $1.72 billion, combined adjusted EBITDA of $741.7 million and net income of $387.3 million, reflecting stronger execution across both its core ingredients business and the Diamond Green Diesel joint venture. The company also reduced net debt by $223 million during the quarter and received $280 million in cash distributions from Diamond Green Diesel, reinforcing its financial flexibility.
Dudley's influence extends beyond acquisitions to portfolio optimization and innovation. She has helped advance initiatives such as the Nextida collagen and gelatin platform while supporting strategic portfolio actions, including acquisitions and divestitures, to enhance long-term profitability. As Darling continues to deploy AI, optimize its global asset base and pursue disciplined growth opportunities, Dudley's strategic leadership is expected to strengthen competitive positioning, improve capital efficiency and support sustainable shareholder value creation. Currently, Darling carries a Zacks Rank #1.
General Dynamics: Phebe N. Novakovic has been the driving force behind General Dynamics' strategic evolution since becoming chairman and chief executive officer in 2013. Her leadership has centered on disciplined capital allocation, operational execution and investment in high-priority defense and aerospace platforms rather than pursuing large-scale acquisitions. This approach has enabled General Dynamics to strengthen its competitive position across nuclear submarines, combat vehicles, secure communications and Gulfstream business jets while maintaining consistent profitability and shareholder returns. Her focus on execution has also helped the company expand margins and generate robust cash flows across economic and defense spending cycles.
Novakovic's strategy is reflected in the company's latest operating performance. In the second quarter of 2026, General Dynamics reported revenues of $14.1 billion, up 8.1% year over year, while operating earnings increased 11.9% to $1.5 billion and EPS rose 13.4% to $4.24. Operating margin expanded 40 basis points to 10.4%, supported by growth across all four business segments. The company also generated $1.9 billion in operating cash flow and $1.6 billion in free cash flow, highlighting the effectiveness of Novakovic's emphasis on operational discipline and cash generation.
Novakovic has transformed General Dynamics into one of the defense industry's most financially resilient companies. Under her leadership, the company has built a record backlog of $136.5 billion, providing multi-year revenue visibility as global defense spending accelerates. Strong order inflows and continued investments to expand production capacity position General Dynamics to capitalize on sustained demand for naval platforms, combat systems and business aviation. Although supply-chain constraints and execution risks persist, Novakovic's conservative financial management and long-term strategic focus continue to support durable earnings growth and shareholder value creation. Currently, General Dynamics carries a Zacks Rank #2 (Buy).
FuelCell: Amanda J. Schreiber joined FuelCell as executive vice president, General Counsel and Corporate Secretary in January 2026, bringing more than two decades of experience in legal, commercial and governance leadership across the global power and infrastructure sectors. At FuelCell, she oversees the company's legal, compliance and corporate governance functions while serving as a strategic advisor to the executive leadership team and board of directors. Her prior experience at ContourGlobal, where she supported international project development, financings and mergers and acquisitions across more than 20 countries, strengthens FuelCell’s ability to execute complex commercial agreements and strategic partnerships in the rapidly evolving clean-energy market.
Schreiber's appointment comes at an important stage in FuelCell’s commercialization strategy. The company is expanding its manufacturing footprint, advancing its carbon capture collaboration with ExxonMobil and pursuing large-scale data center power opportunities, all of which require strong legal oversight and disciplined risk management. During the second quarter of fiscal 2026, FuelCell reported a sales pipeline of 4 gigawatts, up 267% sequentially, while maintaining a backlog of $1.14 billion. Although quarterly revenues declined 5% year over year to $35.6 million, the company strengthened liquidity, ending the quarter with $440.9 million in cash and restricted cash following successful equity raises.
While Schreiber is not directly responsible for operating performance, her contribution is strategically significant. Strong governance, contract execution and regulatory compliance are critical as FuelCell seeks to convert its expanding commercial pipeline into revenues and navigate project financings, technology collaborations and international deployments. Her expertise in enterprise risk management and complex infrastructure transactions should support management's long-term growth strategy, enhance execution discipline and strengthen investor confidence as the company works toward sustainable commercialization and improved financial performance. Currently, FuelCell carries a Zacks Rank #2.
Chemours: Denise M. Dignam has been instrumental in reshaping Chemours since joining the company in 2015, culminating in her appointment as president and chief executive officer in March 2024. Having previously led the Titanium Technologies and Advanced Performance Materials businesses, she brought deep operational expertise to the top role. Under her leadership, Chemours has focused on operational excellence, disciplined capital allocation and portfolio optimization while strengthening governance and restoring stakeholder confidence. Dignam has also emphasized innovation in next-generation refrigerants, advanced materials and titanium technologies, positioning the company to capitalize on long-term sustainability trends and evolving regulatory requirements.
Dignam's strategy is improving the quality of Chemours' operating performance despite a challenging demand environment. In the second quarter of 2026, the company reported net sales of $1.59 billion, broadly flat year over year as pricing gains across all three business segments largely offset lower volumes. Adjusted EBITDA was $247 million, near the high end of management's guidance, while adjusted EPS came in at 42 cents. More importantly, free cash flow increased 128% year over year to $114 million, free cash flow conversion improved to 46%, and net leverage declined to 4.4x, reflecting stronger cash generation and balance sheet improvement.
Dignam's leadership has also strengthened Chemours' long-term strategic positioning. She has accelerated cost-reduction initiatives, advanced the commercialization of Opteon low-global-warming-potential refrigerants and reinforced the company's balance sheet through prudent cash management. While macroeconomic uncertainty and cyclical demand remain challenges, her focus on operational execution, innovation and financial discipline has enhanced Chemours' earnings resilience and positioned the company to benefit from recovering industrial demand and increasing adoption of sustainable technologies. Currently, Chemours carries a Zacks Rank #2.
Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis.
The Chemours Company (CC) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDT
Company Participants
Brandon Ontjes - Vice President of Investor Relations
Denise Dignam - President, CEO & Director
Shane Hostetter - Senior VP & CFO
Conference Call Participants
Peter Osterland - Truist Securities, Inc., Research Division
Patrick Fischer - Goldman Sachs Group, Inc., Research Division
John Ezekiel Roberts - Mizuho Securities USA LLC, Research Division
Hassan Ahmed - Alembic Global Advisors
Joshua Spector - UBS Investment Bank, Research Division
Arun Viswanathan - RBC Capital Markets, Research Division
Caleb Boehnlein - BMO Capital Markets Equity Research
Vincent Andrews - Morgan Stanley, Research Division
Aaron Rosenthal - JPMorgan Chase & Co, Research Division
Presentation
Operator
Good morning. My name is Therese, and I will be your conference operator today. I would like to welcome everyone to The Chemours Company's Second Quarter 2026 Results Conference Call. [Operator Instructions] I would like to remind everyone that this conference call is being recorded. I would now like to hand the conference call over to Brandon Ontjes, Vice President and Head of Strategy and Investor Relations for Chemours. You may begin.
Brandon Ontjes
Vice President of Investor Relations
Good morning, everybody. Welcome to the Chemours Company's Second Quarter 2026 Earnings Conference Call. I'm joined today by Denise Dignam, Chemours' President and Chief Executive Officer; and our Senior Vice President and Chief Financial Officer, Shane Hostetter. Before we start, I would like to remind you that comments made on this call as well as in the supplemental information provided on our website contain forward-looking statements that involve risks and uncertainties as described in Chemours' SEC filings.
These forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events that may not be realized. Actual results may differ, and Chemours undertakes no duty to update any forward-looking
Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand RisesChemours NYSE: CC said its second-quarter results reflected pricing gains, operational improvements and continued execution under its Pathway to Thrive strategy, while softer residential air-conditioning aftermarket demand weighed on sales in its Thermal & Specialized Solutions business.
President and Chief Executive Officer Denise Dignam said second-quarter net sales came in slightly below the company’s expectations, primarily because of softer residential stationary air-conditioning demand in Thermal & Specialized Solutions, or TSS. However, adjusted EBITDA exceeded expectations, helped by stronger operations and product mix in Advanced Performance Materials, lower corporate costs and pricing gains in Titanium Technologies.
Get Chemours alerts:
MarketBeat Week in Review – 06/22 - 06/26“The actions we are taking under Pathway to Thrive are strengthening the business,” Dignam said, citing pricing actions, debt reduction, cash generation and recent settlements with the U.S. Environmental Protection Agency and West Virginia Department of Environmental Protection.
Aftermarket destocking pressures TSS outlook TSS net sales were slightly lower than a year earlier, as lower North American aftermarket sales of Opteon refrigerant blends offset year-over-year growth in OEM volumes and continued growth in data-center-related markets. Higher prices, including strength in Freon refrigerants used primarily in automotive applications, partly mitigated the volume decline.
Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereDignam said the prior-year period benefited from distributor channel filling connected to the U.S. AIM Act transition in stationary air conditioning. That inventory build left the aftermarket with elevated stock entering 2026.
The company said residential demand has also been constrained by higher interest rates, affordability pressures and slower housing activity. A colder spring in the Northeast and broader macroeconomic uncertainty contributed to weaker order activity, executives said.
For the third quarter, Chemours expects TSS net sales to decline sequentially by the mid-teens to 20% range, with adjusted EBITDA of $125 million to $140 million. CFO Shane Hostetter said the outlook reflects seasonal factors and a less favorable mix from lower Opteon aftermarket sales.
Hostetter said the company still views TSS as a business capable of margins above 30% over time. He said the company expects seasonal restocking to begin ahead of the 2027 cooling season, while the expanding installed base of newer residential and light-commercial systems should support longer-term growth.
Chemours expects the stationary aftermarket to grow at a mid- to high-single-digit annual percentage rate over the longer term, supported by equipment replacement activity, heat-pump adoption in Europe and data-center chiller demand.
Titanium Technologies pricing offsets inflation In Titanium Technologies, second-quarter net sales increased slightly from the prior-year quarter, driven primarily by global pricing gains. Volumes declined in key end markets, except in Asian markets excluding China and in Latin America, where demand was more resilient following antidumping duties in Brazil.
Adjusted EBITDA improved year over year, while adjusted EBITDA margin was flat. Chemours said higher pricing more than offset inflation-related costs.
The company has announced three titanium dioxide price increases since December 2025, including a global increase effective June 1. Together, the actions have resulted in an approximately 5% year-to-date increase in pricing compared with the start of the year, according to management.
For the third quarter, Chemours expects Titanium Technologies net sales to rise sequentially in the low- to mid-single-digit percentage range and adjusted EBITDA to total $70 million to $80 million. The company expects volumes to be higher year over year in the second half across all end markets outside China.
Dignam said rising sulfur costs are increasing costs for sulfate-produced titanium dioxide, a trend that predated the war and has since intensified. She said the company remains focused on “fair trade markets” where it believes customers value supply reliability and its product offering.
APM sees data center and semiconductor momentum Advanced Performance Materials sales declined year over year in the second quarter, largely because of the SPS Capstone line closure completed in the third quarter of 2025. Higher prices partially offset the volume impact. Adjusted EBITDA also declined, reflecting the line closure and costs related to the now-resolved Washington Works outage.
Within APM, Performance Solutions sales increased 8% from the prior-year period. Dignam said the business is benefiting from order-book strength in data center and semiconductor applications. More than 40% of Performance Solutions sales are tied to targeted markets including data centers, semiconductors, artificial intelligence and advanced electronics, management said.
Chemours recorded nominal sales of two-phase liquid-cooling products for customer sampling during the quarter. Product trials increased 70% year over year, according to the company. Dignam said commercial liquid cooling today is primarily single-phase, while two-phase liquid cooling represents a potential future opportunity.
For the third quarter, Chemours expects APM sales to increase sequentially in the mid- to high-single-digit percentage range, supported by normalized operations at Washington Works and Performance Solutions order fulfillment. Adjusted EBITDA is expected to be $20 million to $30 million, including about $5 million of sales performance pulled forward into the second quarter.
Full-year outlook and debt reduction Chemours expects third-quarter consolidated net sales to range from down 5% sequentially to flat, with adjusted EBITDA of $175 million to $205 million. Corporate expenses are expected to be approximately $40 million to $45 million, capital expenditures are expected to be about $65 million, and free cash flow is projected to be at least $50 million.
Full-year 2026 net sales are expected to grow 1% to 5% from 2025. Full-year adjusted EBITDA is projected at $775 million to $825 million. Capital expenditures are expected to total $250 million to $280 million. Free-cash-flow conversion is expected to exceed 25%. Net leverage is expected to be about 3.8 times adjusted EBITDA by year-end 2026. The company repaid nearly $270 million of its 2028 euro term loan during the second quarter, including $103 million beyond the amount discussed on its first-quarter call. Hostetter said Chemours intends to continue prioritizing debt repayment through organic cash flow and proceeds received from the Kuan Yin land sale.
Looking beyond 2026, Dignam said Chemours is pursuing strategic and portfolio optionality, including potential partnerships and actions involving product lines or assets. She said no portfolio action is off the table if it could create a “step change” in shareholder value, though she declined to discuss specific potential transactions.
The company said its core businesses could ultimately support at least $1 billion in annual adjusted EBITDA and free-cash-flow conversion exceeding 40%, while it continues to reduce balance-sheet risk.
About Chemours (NYSE:CC)Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours' principal business activities are organized into three core segments.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Chemours Right Now?Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Chemours (CC - Free Report) reported $1.59 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 1.5%. EPS of $0.42 for the same period compares to $0.58 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of -4.97%. The company delivered an EPS surprise of -2.33%, with the consensus EPS estimate being $0.43.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales- Thermal & Specialized Solutions: $591 million versus $666.16 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1% change.Net Sales- Titanium Technologies: $661 million compared to the $661.68 million average estimate based on four analysts. The reported number represents a change of +0.6% year over year.Net Sales- Other Non-Reportable Segment: $13 million compared to the $12.89 million average estimate based on four analysts.Net Sales- Advanced Performance Materials: $326 million versus $333.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -5.8% change.Adjusted EBITDA- Titanium Technologies: $48 million versus the four-analyst average estimate of $45.65 million.Adjusted EBITDA- Thermal & Specialized Solutions: $213 million versus the four-analyst average estimate of $224.96 million.Adjusted EBITDA- Advanced Performance Materials: $26 million versus $15.08 million estimated by four analysts on average.Adjusted EBITDA- Other Non-Reportable Segment: $2 million versus the three-analyst average estimate of $2.69 million.View all Key Company Metrics for Chemours here>>>
Shares of Chemours have returned -5.9% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Chemours (CC - Free Report) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -2.33%. A quarter ago, it was expected that this chemical company would post a loss of $0.05 per share when it actually produced earnings of $0.05, delivering a surprise of +200%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Chemours, which belongs to the Zacks Chemical - Diversified industry, posted revenues of $1.59 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 4.97%. This compares to year-ago revenues of $1.62 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Chemours shares have added about 45.1% since the beginning of the year versus the S&P 500's gain of 11%.
What's Next for Chemours?While Chemours has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Chemours was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.49 on $1.58 billion in revenues for the coming quarter and $1.18 on $6.05 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Diversified is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Kronos Worldwide (KRO - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.
This maker of titanium dioxide pigments is expected to post quarterly loss of $0.04 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Kronos Worldwide's revenues are expected to be $520.34 million, up 5.3% from the year-ago quarter.
, /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the second quarter 2026.
Key Second Quarter 2026 Results & Recent Highlights1
Net Sales of $1.6 billion, approximately flat compared to the corresponding prior-year quarter reflecting pricing increases across all businesses Net Loss attributable to Chemours of $274 million, or $1.81 per diluted share, compared with Net Loss attributable to Chemours of $380 million, or $2.53 per diluted share, in the corresponding prior-year quarter Adjusted Net Income2 of $64 million, or $0.42 per diluted share, compared to Adjusted Net Income of $91 million, or $0.61 per diluted share, in the corresponding prior-year quarter Adjusted EBITDA2,3 of $247 million compared to $260 million in the corresponding prior-year quarter, reflecting a strong prior-year comparison from TSS aftermarket performance Free Cash Flows improved 128% year-over-year, with Free Cash Flow Conversion of 46% and net leverage declining to 4.4x, advancing Chemours toward its long-term target of sustaining leverage below 3x Announced an additional global TiO2 price increase effective June 1, 2026, contributing to an approximately 5% year-to-date TiO2 price increase in Net Sales APM Performance Solutions Net Sales grew 8% year-over-year, underscoring momentum and mix shift towards high-value specialty products serving data center and semiconductor end market "Our second quarter results reflect disciplined execution across our portfolio, with Adjusted EBITDA near the high end of our guidance range and Free Cash Flows above our expectations despite a dynamic macroeconomic environment," said Denise Dignam, Chemours President and CEO. "Progress on pricing actions in Titanium Technologies to drive value, and increased sales in APM's high-value Performance Solutions portfolio supporting our momentum serving data center and semiconductor applications, and continued traction in our liquid cooling solutions, highlight our efforts to drive commercial excellence and growth."
Dignam continued, "Chemours also made meaningful progress strengthening its balance sheet through improved cash generation and reduced gross debt, while advancing resolution of notable legacy litigation. Looking ahead to the second half of the year, we remain focused on the actions within our control and committed to executing against our Pathway to Thrive strategy."
Total Chemours
Q2 2026
Q2 2025
Y-o-Y % ∆
Q1 2026
Q-o-Q % ∆
Net Sales (millions)
$1,591
$1,615
(1) %
$1,381
15 %
Net Income (Loss) attributable to
Chemours (millions)
($274)
($380)
28 %
($29)
(845 %)
Earnings (Loss) Per Share4
($1.81)
($2.53)
28 %
($0.19)
(853 %)
Adjusted Net Income
$64
$91
(30 %)
$8
700 %
Adjusted EPS
$0.42
$0.61
(31 %)
$0.05
740 %
Adjusted EBITDA (millions)
$247
$260
(5) %
$169
46 %
Second quarter 2026 Net Sales were approximately $1.6 billion, a decrease of approximately 1% compared to the prior-year quarter. The year-over-year decrease in Net Sales was driven by a 4% decrease in volumes, partially offset by a 2% increase in price and a 1% currency tailwind. The volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act, as well as lower volumes associated with the APM SPS Capstone™ line closure completed in the third quarter of 2025. These volume headwinds were partially offset by pricing strength across all three segments, including price increases in TT.
Second quarter 2026 Net Loss attributable to Chemours was ($274) million, or ($1.81) per diluted share, compared to Net Loss attributable to Chemours of ($380) million, or ($2.53) per diluted share, in the prior-year quarter. The prior-year second quarter loss includes the impact of the announced settlement with the State of New Jersey and related legal and environmental reserves recognized and corresponding tax impacts, while the current-year second quarter loss includes the impact of legal and environmental reserves related to the announced settlement with the EPA and WVDEP as well as ongoing litigation, and corresponding tax impacts, partially offset by a gain on the Kuan Yin property sales. Second quarter Adjusted Net Income decreased compared with the prior-year quarter, primarily due to additional income tax impacts related to the Kuan Yin property sales completed during the second quarter of 2026.
Adjusted EBITDA for the second quarter of 2026 was $247 million, compared to $260 million in the prior-year quarter. The decrease was driven by the anticipated higher APM costs associated with the recently resolved outage at the Washington Works site, as well as lower sales from APM's SPS Capstone™ line closure completed in the third quarter of 2025, partially offset by pricing increases across all segments.
Thermal & Specialized Solutions
Q2 2026
Q2 2025
Y-o-Y % ∆
Q1 2026
Q-o-Q % ∆
Net Sales (millions)
$591
$597
(1) %
$568
4 %
Opteon™ Refrigerants
$337
$375
(10) %
$313
8 %
Freon™ Refrigerants
$150
$123
22 %
$162
(7) %
Foam, Propellants & Other (FP&O)
$104
$99
5 %
$93
12 %
Adjusted EBITDA (millions)
$213
$207
3 %
$190
12 %
Adjusted EBITDA Margin
36 %
35 %
1 ppts
33 %
3 ppts
TSS segment second quarter 2026 Net Sales were $591 million, a decrease of 1% versus the prior-year quarter, driven by a 4% decrease in volumes, partially offset by a 2% increase in price and a slight currency tailwind.
The decrease in volumes was primarily attributable to lower stationary AC aftermarket refrigerant sales of TSS Opteon™ blends in North America, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with the stationary technology AC transition under the U.S. AIM Act, partially offset by higher Freon™ prices, primarily in automotive applications.
Adjusted EBITDA for the quarter increased 3% to $213 million, while Adjusted EBITDA Margin increased one point to 36%. The increase in Adjusted EBITDA was driven by higher pricing, aided by the timing of certain costs in the quarter.
Sequentially, TSS Net Sales increased 4%, driven by a 5% seasonal volume increase, partially offset by mix-related pricing and currency headwinds.
Titanium Technologies
Q2 2026
Q2 2025
Y-o-Y % ∆
Q1 2026
Q-o-Q % ∆
Net Sales (millions)
$661
$657
1 %
$559
18 %
TiO2 Pigment
$639
$629
2 %
$541
18 %
Minerals
$22
$28
(21 %)
$18
22 %
Adjusted EBITDA (millions)
$48
$47
2 %
$18
167 %
Adjusted EBITDA Margin
7 %
7 %
0 ppts
3 %
4 ppts
TT segment second quarter 2026 Net Sales were $661 million, a 1% increase compared to the prior-year quarter. The increase was driven by a 2% increase in global pricing and a 1% currency tailwind, more than offsetting a 2% decline in global volumes. Pricing increased across all regions, while the volume decline was driven by lower TiO2 sales across key end markets, with the exception of Asia, excluding China, and Latin America.
TT segment second quarter 2026 Adjusted EBITDA increased to $48 million from $47 million in the prior-year quarter, while Adjusted EBITDA Margin was flat. The increase in Adjusted EBITDA was primarily driven by the global pricing strength noted above, partially offset by higher costs due to inflation.
Sequentially, TT segment second quarter 2026 Net Sales increased 18%, driven by a 15% increase in global volumes and a 3% increase in price, reflecting continued execution of recent TiO2 pricing actions. Sequential price and volume increases were reflected across all regions.
Advanced Performance Materials
Q2 2026
Q2 2025
Y-o-Y % ∆
Q1 2026
Q-o-Q % ∆
Net Sales (millions)
$326
$346
(6 %)
$243
34 %
Advanced Materials
$184
$214
(14 %)
$143
29 %
Performance Solutions
$142
$132
8 %
$100
42 %
Adjusted EBITDA (millions)
$26
$50
(48 %)
$5
420 %
Adjusted EBITDA Margin
8 %
14 %
(6) ppt
2 %
6 ppts
APM segment second quarter 2026 Net Sales were $326 million, a 6% decrease compared to the prior-year quarter. The decrease was driven by a 9% decrease in volumes, partially offset by a 2% increase in price and a slight currency tailwind. The volume decline was primarily driven by the APM SPS Capstone™ line closure completed in the third quarter of 2025. Performance Solutions Net Sales increased 8% year-over-year, supported by order book strength and continued momentum in high-value specialty products serving data center and semiconductor end markets.
APM segment second quarter 2026 Adjusted EBITDA decreased 48% to $26 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased six percentage points to 8%. The decrease in Adjusted EBITDA was primarily driven by lower sales associated with the SPS Capstone™ line closure, as well as higher costs from the now-resolved outage at the Washington Works site.
Sequentially, APM segment second quarter 2026 Net Sales increased approximately 34%, driven by a 31% increase in volumes reflecting more normalized operations at the Washington Works site and a 4% pricing uplift, partially offset by a slight currency headwind. Performance Solutions Net Sales increased 42% sequentially, reflecting continued order book strength and momentum in high-value specialty products serving data center and semiconductor end markets.
Other Non-Reportable Segment
The Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the second quarter 2026 of $13 million and $2 million, respectively.
Corporate Expenses
Corporate Expenses were $42 million in the second quarter of 2026, a decrease of approximately $4 million compared to the prior-year quarter. This was primarily due to lower costs associated with legacy litigation activities.
Liquidity and Capital Allocation
As of June 30, 2026, consolidated gross debt was $3.9 billion. Debt, net of $671 million in unrestricted cash and cash equivalents, was $3.2 billion, resulting in a net leverage ratio of approximately 4.4x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.6 billion, comprised of $671 million in unrestricted5 cash and cash equivalents and $953 million of revolving credit facility capacity, net of outstanding letters of credit.
During the quarter, the Company paid down €230 million of the outstanding tranche of the B-3 Euro-denominated Term Loan due August 2028, using a mixture of proceeds from the previously announced Kuan Yin land sale and organic cash. The Company anticipates further debt repayments in 2026.
Operating cash flows for the second quarter of 2026 were $158 million, compared to $93 million in the prior-year quarter, highlighting improvements in net working capital performance.
Capital expenditures for the second quarter of 2026 amounted to $44 million, an increase compared to $43 million in the prior-year quarter.
Free Cash Flows for the second quarter of 2026 were $114 million, compared to $50 million in the second quarter of 2025.
Third Quarter 2026 Outlook
In the third quarter, the Company expects consolidated Net Sales to decrease in the range of 5% to flat, sequentially, driven by weaker Opteon™ blends aftermarket refrigerant demand in TSS, with consolidated Adjusted EBITDA expected to range between $175 million and $205 million. Corporate Expenses are expected to approximate $40 million to $45 million. The Company also anticipates capital expenditures to approximate $65 million, with Free Cash Flows of at least $50 million, reflecting the timing of payments for plant turnaround activities commencing later in the third quarter.
TSS expects Net Sales will sequentially decrease in the mid-teens to 20% range, driven by less favorable seasonality in connection with the 2026 cooling season in the Northern Hemisphere and weaker Opteon™ blends aftermarket refrigerant demand in North America due to elevated market inventory levels from the initial channel fill in mid-2025. Adjusted EBITDA is expected to be between $125 million and $140 million.
TT expects a sequential Net Sales increase in the low-to-mid single-digit percentage range, driven by recent pricing announcements, with stable volumes. Adjusted EBITDA is expected to range between $70 million and $80 million.
APM expects a sequential Net Sales increase in the mid-to-high single digit percentage range, driven by a return to normal operating levels at the Washington Works facility and continued strength in the Performance Solutions order book in high-value specialty products primarily serving data center and semiconductor end markets. Adjusted EBITDA for APM is expected to be between $20 million and $30 million.
Full Year 2026 Outlook
The Company continues to expect 2026 Net Sales to grow in the range of 1% to 5% over 2025, with Adjusted EBITDA between $775 million and $825 million. Moving later into the second half, this outlook is supported by broader pricing momentum in TT with seasonal volume declines offset by anticipated cost improvements, APM's demand strength in high-value end markets supported by operational improvements driving earnings above near-term levels, and TSS aftermarket weakness driving slightly weaker earnings to end the year. Capital expenditures are anticipated to be between $250 million and $280 million, with overall Free Cash Flow Conversion above 25%, due to increased earnings and improvements in working capital throughout the year. The Company continues to anticipate achieving a net leverage ratio of around 3.8x by the end of 2026.
Conference Call
As previously announced, Chemours will hold a conference call and webcast on August 5, 2026, at 8:00 AM Eastern Daylight Time. The webcast and materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours' investor website.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.
Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the third quarter of 2026, the full year 2026 and the Company's corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
1 Certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Annual Report on Form 10-K for the year ended December 31, 2025.
2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".
3 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.
4 On a diluted earnings per share basis.
5 Restricted cash approximated $52 million of the end of the second quarter of 2026, reflecting primarily escrow payments Chemours has made related to the MOU agreement with DuPont, Corteva and EID as further described in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
The Chemours Company
Consolidated Statements of Operations (Unaudited)1
(Dollars in millions, except per share amounts)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Net sales
$
1,591
$
1,615
$
2,972
$
2,983
Cost of goods sold
1,305
1,337
2,474
2,469
Gross profit
286
278
498
514
Selling, general, and administrative expense
469
424
616
547
Research and development expense
27
28
53
55
Restructuring, asset-related, and other charges
3
18
16
51
Total other operating expenses
499
470
685
653
Equity in earnings of affiliates
9
9
17
17
Interest expense, net
(68)
(67)
(137)
(133)
Loss on extinguishment of debt
(2)
—
(11)
—
Other income, net
273
2
296
6
Loss before income taxes
(1)
(248)
(22)
(249)
Provision for income taxes
273
131
281
135
Net loss
(274)
(379)
(303)
(384)
Less: Net income attributable to non-controlling interests
—
1
—
1
Net loss attributable to Chemours
$
(274)
$
(380)
$
(303)
$
(385)
Per share data
Basic (loss) earnings per share of common stock
$
(1.81)
$
(2.53)
$
(2.01)
$
(2.56)
Diluted (loss) earnings per share of common stock
(1.81)
(2.53)
(2.01)
(2.56)
The Chemours Company
Consolidated Balance Sheets (Unaudited)1
(Dollars in millions, except per share amounts)
June 30, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
671
$
670
Restricted cash and restricted cash equivalents
—
2
Accounts and notes receivable, net
907
679
Inventories
1,452
1,569
Prepaid expenses and other
63
80
Assets held for sale
1
1
Total current assets
3,094
3,001
Property, plant, and equipment
9,993
9,920
Less: Accumulated depreciation
(6,965)
(6,842)
Property, plant, and equipment, net
3,028
3,078
Operating lease right-of-use assets
270
271
Goodwill
46
46
Other intangible assets, net
2
2
Investments in affiliates
170
160
Assets held for sale, non-current
—
21
Restricted cash and restricted cash equivalents
52
52
Other assets
488
751
Total assets
$
7,150
$
7,382
Liabilities
Current liabilities:
Accounts payable
$
937
$
954
Compensation and other employee-related cost
83
96
Short-term and current maturities of long-term debt
34
42
Current environmental remediation
124
88
Other accrued liabilities
683
506
Total current liabilities
1,861
1,686
Long-term debt, net
3,838
4,099
Operating lease liabilities
191
191
Long-term environmental remediation
671
530
Deferred income taxes
64
37
Other liabilities
573
588
Total liabilities
7,198
7,131
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized;
199,276,562 shares issued and 150,463,268 shares outstanding at June 30,
2026; 198,720,786 shares issued and 149,893,993 shares outstanding at
December 31, 2025)
2
2
Treasury stock, at cost (48,813,294 shares at June 30, 2026 and 48,826,793 at
December 31, 2025)
(1,801)
(1,802)
Additional paid-in capital
1,088
1,074
Retained earnings
891
1,220
Accumulated other comprehensive loss
(229)
(244)
Total Chemours stockholders' equity
(49)
250
Non-controlling interests
1
1
Total equity
(48)
251
Total liabilities and equity
$
7,150
$
7,382
The Chemours Company
Consolidated Statements of Cash Flows (Unaudited)1
(Dollars in millions)
Six Months Ended June 30,
2026
2025
Cash flows from operating activities
Net loss
$
(303)
$
(384)
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization
159
180
Gain on sales of assets and businesses
(266)
(1)
Equity in earnings of affiliates, net
(10)
(16)
Loss on extinguishment of debt
11
—
Amortization of debt issuance costs and issue discounts
5
6
Deferred tax provision
238
97
Asset-related charges
1
11
Stock-based compensation expense
14
12
Net periodic pension (income) cost
(1)
—
Defined benefit plan contributions
(1)
(8)
Other operating charges and credits, net
(9)
14
Decrease (increase) in operating assets:
Accounts and notes receivable, net
(218)
(174)
Inventories and other current operating assets
114
(42)
Other non-current operating assets
53
64
(Decrease) increase in operating liabilities:
Accounts payable
(12)
(87)
Other current operating liabilities
217
70
Other non-current operating liabilities
122
239
Cash provided by (used for) operating activities
114
(19)
Cash flows from investing activities
Purchases of property, plant, and equipment
(93)
(127)
Proceeds from life insurance policies
1
—
Proceeds from sales of assets and businesses
294
1
Foreign exchange contract settlements, net
(7)
(2)
Cash provided by (used for) investing activities
195
(128)
Cash flows from financing activities
Proceeds from issuance of debt
700
95
Debt repayments
(963)
(111)
Payments on finance leases
(5)
(7)
Payments of debt issuance cost
(10)
(4)
Proceeds from supplier financing program
32
47
Payments to supplier financing program
(31)
(53)
Proceeds from exercised stock options, net
3
—
Payments related to tax withholdings on vested stock awards
(2)
(1)
Payments of dividends to the Company's common shareholders
(26)
(50)
Debt extinguishment payments
(6)
—
Cash used for financing activities
(308)
(84)
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash
equivalents
(2)
21
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents
(1)
(210)
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,
724
763
Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30,
$
723
$
553
Supplemental cash flows information
Non-cash investing and financing activities:
Purchases of property, plant, and equipment included in accounts payable
$
26
$
26
The Chemours Company
Segment Financial and Operating Data (Unaudited)
(Dollars in millions)
Segment Net Sales1
Three Months
Ended
Sequential
Three Months Ended June 30,
Increase /
March 31,
Increase /
2026
2025
(Decrease)
2026
(Decrease)
Thermal & Specialized Solutions
$
591
$
597
$
(6)
$
568
$
23
Titanium Technologies
661
657
4
559
102
Advanced Performance
Materials
326
346
(20)
243
83
Other Non-Reportable Segment
13
15
(2)
11
2
Total Net Sales
$
1,591
$
1,615
$
(24)
$
1,381
$
210
Segment Adjusted EBITDA1
Three Months
Ended
Sequential
Three Months Ended June 30,
Increase /
March 31,
Increase /
2026
2025
(Decrease)
2026
(Decrease)
Thermal & Specialized Solutions
$
213
$
207
$
6
$
190
$
23
Titanium Technologies
$
48
$
47
$
1
$
18
$
30
Advanced Performance
Materials
$
26
$
50
$
(24)
$
5
$
21
Other Non-Reportable Segment
$
2
$
4
$
(2)
$
3
$
(1)
Quarterly Change in Net Sales from the three months ended June 30, 2025
June 30, 2026
Percentage Change
vs.
Percentage Change Due To
Net Sales
June 30, 2025
Price
Volume
Currency
Portfolio
Total Company
$
1,591
(1)
%
2
%
(4)
%
1
%
—
%
Thermal & Specialized Solutions
$
591
(1)
%
2
%
(4)
%
1
%
—
%
Titanium Technologies
661
1
%
2
%
(2)
%
1
%
—
%
Advanced Performance
Materials
326
(6)
%
2
%
(9)
%
1
%
—
%
Other Non-Reportable Segment
13
(12)
%
(4)
%
(8)
%
—
%
—
%
Quarterly Change in Net Sales from the three months ended March 31, 2026
June 30, 2026
Percentage Change
vs.
Percentage Change Due To
Net Sales
March 31, 2026
Price
Volume
Currency
Portfolio
Total Company
$
1,591
15
%
2
%
13
%
—
%
—
%
Thermal & Specialized
Solutions
$
591
4
%
(1)
%
5
%
—
%
—
%
Titanium Technologies
661
18
%
3
%
15
%
—
%
—
%
Advanced Performance
Materials
326
34
%
4
%
31
%
(1)
%
—
%
Other Non-Reportable
Segment
13
19
%
(5)
%
24
%
—
%
—
%
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
GAAP Net Loss Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation1
Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
Three Months Ended
Six Months Ended
Twelve Months Ended
June 30,
March 31,
June 30,
June 30,
2026
2025
2026
2026
2025
2026
2025
Loss before income taxes
$
(1)
$
(248)
$
(22)
$
(22)
$
(249)
$
(52)
$
(292)
Net loss attributable to Chemours
$
(274)
$
(380)
$
(29)
$
(303)
$
(385)
$
(303)
$
(428)
Non-operating pension and other post-
retirement benefit income
(3)
(2)
(2)
(5)
(4)
(12)
(5)
Exchange losses (gains), net
1
4
(1)
1
7
5
10
Restructuring, asset-related, and other
charges (1)
3
18
13
16
50
24
100
Goodwill impairment charge (2)
—
—
—
—
—
—
56
Loss on extinguishment of debt (3)
2
—
9
11
—
16
1
Gain on sales of assets and businesses,
net (4)
(266)
—
—
(266)
(1)
(273)
(1)
Transaction costs (5)
—
2
2
2
2
6
4
Qualified spend recovery (6)
(6)
(13)
(5)
(11)
(22)
(31)
(33)
Litigation-related charges (7)
225
293
20
244
293
272
296
Environmental charges (8)
144
60
7
150
60
184
75
Adjustments made to income taxes (9)
207
179
1
208
181
209
191
Provision for (benefit from) income taxes
relating to reconciling items (10)
31
(70)
(7)
25
(70)
8
(81)
Adjusted Net Income
64
91
8
72
111
105
185
Net income attributable to non-controlling
interests
—
1
—
—
1
(1)
1
Interest expense, net
68
67
69
137
133
273
268
Depreciation and amortization (11)
80
79
79
159
157
320
304
All remaining provision for income taxes
(10)
35
22
13
48
24
36
37
Adjusted EBITDA
$
247
$
260
$
169
$
416
$
426
$
733
$
795
Total debt principal
$
3,914
$
4,183
Less: Cash and cash equivalents
(671)
(502)
Total debt principal, net
$
3,243
$
3,681
Net Leverage Ratio (calculated using
GAAP earnings) (12)
(62.4)x
(12.6)x
Net Leverage Ratio (calculated using
Non-GAAP earnings) (12)
4.4x
4.6x
GAAP Net Loss Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)1
(1)
For the twelve months ended June 30, 2026, restructuring, asset-related and other charges primarily includes employee separation charges related to the 2026 Restructuring Program as well as charges related to our decision to exit our SPS CapstoneTM business. For the twelve months ended June 30, 2025, restructuring, asset-related and other charges primarily include charges related to our decision to exit our SPS CapstoneTM business and the 2024 Restructuring Program. See "Note 4 –Restructuring, Asset-Related and Other Charges" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.
(2)
For the twelve months ended June 30, 2025, this represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2025.
(3)
For the twelve months ended June 30, 2026, loss on extinguishments of debt reflects costs associated with early redemption of the 2027 senior unsecured notes and partial early redemption of our 2028 senior unsecured notes during the second quarter of 2026. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.
(4)
For the twelve months ended June 30, 2026, gain on sales of assets and businesses, net includes a gain on sale of $273 million, primarily related to certain parcels of land at the Company's manufacturing site in Kuan Yin, Taiwan. See "Note 10 - Property, Plant, and Equipment, Net" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.
(5)
For the twelve months ended June 30, 2026, transaction costs include $4 million of costs associated with the Senior Secured Credit Facilities. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.
(6)
Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
(7)
Litigation-related charges pertain to certain litigation settlements and reserves established, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended June 30, 2026 and June 30, 2025, litigation-related charges includes $256 and $289 million related to PFOA and PFAS matters, respectively. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.
(8)
Environmental charges pertain to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended June 30, 2026, environmental charges primarily include changes to remediation reserves related to the Consent Decree entered into with the Environmental Protection Agency, ("EPA"), as well as the West Virginia Department of Environmental Protection ("WVDEP") in the second quarter of 2026. For the twelve months ended June 30, 2025, environmental charges primarily include changes to remediation reserves at the four sites covered by the New Jersey settlement agreement and off-site remediation costs at Dordrecht Works. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.
(9)
Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.
(10)
The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.
(11)
For the twelve months ended June 30, 2025, accelerated depreciation charges of $23 million, incurred as part of our decision to exit our SPS CapstoneTM business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.
(12)
Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by income (loss) before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation1
Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which include unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.
Three Months Ended
Six Months Ended
June 30,
March 31,
June 30,
2026
2025
2026
2026
2025
Numerator:
Net loss attributable to Chemours
$
(274)
$
(380)
$
(29)
$
(303)
$
(385)
Adjusted Net Income
64
91
8
72
111
Denominator:
Weighted-average number of common shares
outstanding - basic
151,225,044
150,238,691
150,767,077
150,997,325
150,078,085
Dilutive effect of the Company's employee
compensation plans (1)
1,588,513
268,070
819,728
1,204,120
379,632
Weighted-average number of common shares
outstanding - diluted (1)
152,813,557
150,506,761
151,586,805
152,201,445
150,457,717
Basic loss per share of common stock (2)
$
(1.81)
$
(2.53)
$
(0.19)
$
(2.01)
$
(2.56)
Diluted loss per share of common stock (1) (2)
(1.81)
(2.53)
(0.19)
(2.01)
(2.56)
Adjusted basic earnings per share of common
stock (2)
0.42
0.61
0.05
0.47
0.74
Adjusted diluted earnings per share of common
stock (1) (2)
0.42
0.61
0.05
0.47
0.74
(1)
In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three and six months ended June 30, 2026 and the three months ended March 31, 2026. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and six months ended June 30, 2026 and the three months ended March 31, 2026 as Adjusted Net Income was in a net income position.
(2)
Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation
Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
Three Months Ended
Six Months Ended
June 30,
March 31,
June 30,
2026
2025
2026
2026
2025
Cash flows provided by (used for)
operating activities
$
158
$
93
$
(44)
$
114
$
(19)
Less: Purchases of property, plant, and
equipment
(44)
(43)
(49)
(93)
(127)
Free Cash Flows
$
114
$
50
$
(93)
$
21
$
(146)
Adjusted EBITDA
247
260
169
416
426
Free Cash Flow Conversion
46
%
19
%
(55)
%
5
%
(34)
%
2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free
Cash Flow Conversion Reconciliation (1)
Free Cash Flows is defined as cash flows provided by operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
Estimated
Year Ended December 31, 2026
Low
High
Cash flows provided by operating activities
$
445
$
525
Less: Purchases of property, plant, and equipment
(250)
(280)
Free Cash Flows
$
195
$
245
Adjusted EBITDA
775
825
Free Cash Flow Conversion
25
%
30
%
(1)
Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site.
2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted
EBITDA Reconciliation (1)
(Estimated)
Year Ending December 31, 2026
Low
High
Net loss attributable to Chemours
$
(255)
$
(230)
Restructuring, transaction, and other costs, net (2)
375
375
Adjusted Net Income
120
145
Interest expense, net
270
280
Depreciation and amortization
320
320
All remaining provision for income taxes
65
80
Adjusted EBITDA
$
775
$
825
(1)
The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.
(2)
Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.
, /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC) today announced that the Board of Directors of Chemours declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the third quarter of 2026. The dividend will be paid on September 15, 2026, to stockholders of record as of the close of business on August 14, 2026.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
Shares of The Chemours Company (NYSE:CC – Get Free Report) have received an average rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $24.10.
Several analysts have commented on the stock. Morgan Stanley raised their price objective on shares of Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. Mizuho decreased their target price on Chemours from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, July 1st. UBS Group increased their target price on Chemours from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Zacks Research upgraded Chemours from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Chemours in a research report on Friday, July 17th.
Check Out Our Latest Stock Report on Chemours
Institutional Trading of Chemours A number of hedge funds have recently modified their holdings of the business. Parallel Advisors LLC increased its stake in shares of Chemours by 10.9% in the 1st quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock worth $118,000 after acquiring an additional 527 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in Chemours by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock worth $404,000 after acquiring an additional 600 shares in the last quarter. PFG Investments LLC boosted its stake in Chemours by 7.6% during the fourth quarter. PFG Investments LLC now owns 12,494 shares of the specialty chemicals company’s stock worth $147,000 after acquiring an additional 883 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in Chemours by 1.2% in the fourth quarter. State of Alaska Department of Revenue now owns 76,257 shares of the specialty chemicals company’s stock worth $899,000 after purchasing an additional 932 shares during the period. Finally, Man Group plc grew its holdings in Chemours by 0.4% in the second quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock worth $3,104,000 after purchasing an additional 979 shares during the period. Institutional investors own 76.26% of the company’s stock.
Chemours Stock Down 3.6% Shares of NYSE CC opened at $16.45 on Monday. The company has a current ratio of 1.82, a quick ratio of 0.87 and a debt-to-equity ratio of 18.98. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The firm has a market capitalization of $2.47 billion, a PE ratio of -6.23 and a beta of 1.41. The firm has a fifty day simple moving average of $20.02 and a two-hundred day simple moving average of $19.99.
Chemours (NYSE:CC – Get Free Report) last announced its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the firm posted $0.13 EPS. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. Equities analysts expect that Chemours will post 1.18 earnings per share for the current year.
Chemours Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were given a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.35 annualized dividend and a yield of 2.1%. Chemours’s dividend payout ratio (DPR) is currently -13.26%.
About Chemours (Get Free Report)
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours’ principal business activities are organized into three core segments.
Featured Stories Five stocks we like better than Chemours Why SK hynix Could Be the Best AI Chip Stock to Buy Now Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEMagnolia Oil & Gas (NYSE:MGY) and Topaz Resources (OTCMKTS:TOPZ) Head-To-Head Analysis
NEXT HEADLINE »Williams-Sonoma, Inc. (NYSE:WSM) Receives $213.12 Average Price Target from Analysts
Investors in The Chemours Company (CC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $6.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Chemours shares, but what is the fundamental picture for the company? Currently, Chemours is a Zacks Rank #1 (Strong Buy) in the Chemical - Diversified industry that ranks in the Top 38% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from 51 cents per share to 49 cents in that period.
Given the way analysts feel about Chemours right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One stock to keep an eye on is Chemours (CC - Free Report) . CC is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value. The stock is trading with a P/E ratio of 8.39, which compares to its industry's average of 13.65. CC's Forward P/E has been as high as 13.52 and as low as 4.73, with a median of 7.76, all within the past year.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. CC has a P/S ratio of 0.44. This compares to its industry's average P/S of 0.73.
Value investors will likely look at more than just these metrics, but the above data helps show that Chemours is likely undervalued currently. And when considering the strength of its earnings outlook, CC sticks out as one of the market's strongest value stocks.
The market expects Chemours (CC - Free Report) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 4. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis chemical company is expected to post quarterly earnings of $0.43 per share in its upcoming report, which represents a year-over-year change of -25.9%.
Revenues are expected to be $1.67 billion, up 3.7% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 4.43% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Chemours?For Chemours, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +27.17%.
On the other hand, the stock currently carries a Zacks Rank of #1.
So, this combination indicates that Chemours will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Chemours would post a loss of$0.05 per share when it actually produced earnings of $0.05, delivering a surprise of +200.00%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Chemours appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAnother stock from the Zacks Chemical - Diversified industry, Huntsman (HUN - Free Report) , is soon expected to post earnings of $0.06 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +130%. Revenues for the quarter are expected to be $1.55 billion, up 6% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Huntsman has been revised 5.9% up to the current level. Nevertheless, the company now has an Earnings ESP of +4.31%, reflecting a higher Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Huntsman will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Chemical companies’ second-quarter results are expected to reflect a recovery in demand in certain key markets and the end of customer inventory de-stocking. Improved demand in automotive and a rebound in construction end markets are likely to have supported their performance. The results of chemical makers are also likely to have been aided by effective self-help actions, including pricing, cost-saving and productivity improvement initiatives.
We have handpicked a few chemical companies — The Chemours Company (CC - Free Report) , Methanex Corporation (MEOH - Free Report) , Avient Corporation (AVNT - Free Report) , DuPont de Nemours, Inc. (DD - Free Report) — which are set to beat earnings estimates this earnings season.
How Have Things Shaped Up for Chemical Stocks?Companies in the chemical space are expected to have benefited from an uptick in demand in certain major markets. The chemical industry bore the brunt of a demand slowdown and continued customer inventory de-stocking last year. The downturn in the key building & construction and consumer electronics markets played spoilsport. In North America, uncertainties surrounding the U.S. housing market have weighed on building & construction. Elevated borrowing costs and inflation took a bite out of the residential construction industry.
The consumer electronics market, a key driver of demand for specialty chemicals and advanced materials, was among the hardest hit. Global electronics demand cooled amid high inflation, elevated interest rates and cautious consumer behavior.
The automotive sector represents a crucial end market for chemical manufacturers. A decline in global vehicle production last year weighed on demand from this segment. Elevated interest rates, coupled with economic slowdown concerns and tariff-related uncertainties, further pressured the market. The automotive industry is expected to rebound this year, supported by accelerating electric vehicle adoption as governments worldwide advance carbon-neutral initiatives. Better affordability, robust demand for hybrid models and aggressive promotional incentives are expected to lift new vehicle sales. As production picks up, the recovery momentum is likely to strengthen through the year.
Chemical companies are also seeing signs of a recovery in demand across the construction and electronics markets. Demand in healthcare and packaging markets also remains steady. On a further positive note, customer inventory destocking in building & construction and consumer durables has largely ended, leading to low inventory levels. This is expected to have led to an uptick in chemical demand and volumes.
Also, the benefits of strategic actions, including those to raise the selling prices of chemical products, cost-cutting and productivity improvement, operational efficiency enhancement, strategic acquisitions and actions to strengthen the balance sheet and boost cash flows, are expected to reflect on the performance of companies in this space in the June quarter.
Partly offsetting these tailwinds, chemical makers are likely to have faced challenges from raw-material and energy-cost inflation and supply-chain and freight-transportation disruptions. Tariffs have led to increased costs for raw materials, resulting in higher production expenses for the industry players. Moreover, the Middle East conflict and the blockade of the Strait of Hormuz have led to significant supply disruptions and feedstock cost pressure. The impacts of inflationary pressures are expected to have reflected on the margins of chemical companies in the second quarter.
Expectations for Q2The chemical industry is housed within the broader Zacks Basic Materials sector. Basic Materials is among the Zacks sectors that are expected to see double-digit growth in earnings for the second quarter. Overall earnings for the space are projected to increase 44.4% on 14.9% higher revenues, per the latest Earnings Trends.
How to Pick Winners?Given the large number of players operating in the chemical space, picking the right stocks is apparently not an easy task. But our proprietary methodology makes it fairly simple. One can trim the list with the combination of a favorable Zacks Rank — Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — and a positive Zacks Earnings ESP. You can uncover the best stocks to buy or sell before they report with our Earnings ESP Filter.
Earnings ESP — the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate — is our proprietary methodology for determining stocks that have high chances of delivering earnings surprises in their next announcements. Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as much as 70%.
Our ChoicesBelow, we list four chemical stocks that have the right combination of elements to pull off an earnings surprise this time around:
Chemours has an Earnings ESP of +27.17% and sports a Zacks Rank #1. The company is scheduled to report on Aug. 4.
Chemours has a trailing four-quarter earnings surprise of roughly 69.8%, on average. The Zacks Consensus Estimate for second-quarter earnings stands at 43 cents. CC is expected to have benefited from seasonal volume strength in the quarter to be reported, driving top-line growth. Benefits from proactive cost-reduction and productivity initiatives aimed at supporting margin expansion are expected to reflect on its performance. Continued transition to Opteon Refrigerants and automotive Freon Refrigerant sales in North America are likely to have supported volume growth in the Thermal & Specialized Solutions segment.
Methanex has an Earnings ESP of +0.06% and carries a Zacks Rank #2. It is slated to report on July 28. You can see the complete list of today’s Zacks #1 Rank stocks here.
Methanex missed the Zacks Consensus Estimate in three of the trailing four quarters and beat once. The company has a trailing four-quarter negative earnings surprise of roughly 27.7%, on average. The Zacks Consensus Estimate for second-quarter earnings stands at 4 cents. MEOH is expected to have seen strong operating performance across its global production network, supported by improved natural gas availability in key regions and reliable contributions from newly acquired assets. Its production is likely to have been supported by additional output from Beaumont and Natgasoline, added from OCI’s methanol business acquisition. Higher realized methanol prices, aided by the supply disruptions stemming from the Middle East conflict, are also expected to have driven its top line and margins.
Avient has an Earnings ESP of +0.87% and carries a Zacks Rank #2. The company is scheduled to report on Aug. 6.
Avient surpassed the Zacks Consensus Estimate in each of the trailing four quarters at an average of 2.1%. The Zacks Consensus Estimate for earnings is pegged at 89 cents. AVNT is likely to have gained from the strength in sustainable solutions, cost-reduction actions and new business wins. Its mix toward defense, healthcare, telecom and chip packaging continues to support margins despite uneven volumes. Price/mix and productivity are expected to have contributed to margin expansion. Growth in healthcare and stable packaging are likely to have supported results.
DuPont has an Earnings ESP of +0.25% and carries a Zacks Rank #3. It is slated to report on Aug. 4.
DuPont surpassed the Zacks Consensus Estimate in each of the trailing four quarters. The company has a trailing four-quarter earnings surprise of roughly 8%, on average. The Zacks Consensus Estimate for second-quarter earnings stands at $1.76. DD’s second-quarter results are likely to have been supported by its innovation-driven investment, productivity actions and the contributions of acquisitions. Continued strength in healthcare and aerospace end markets is expected to have aided its performance. The benefits of its structural cost actions and strategic price increases are expected to reflect on its performance. DD continues to implement strategic price increases in the wake of raw material and energy cost inflation.
Fifth Third Bancorp increased its holdings in The Chemours Company (NYSE:CC – Free Report) by 2,624.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,588 shares of the specialty chemicals company’s stock after purchasing an additional 39,098 shares during the period. Fifth Third Bancorp’s holdings in Chemours were worth $894,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Atlas Capital Advisors Inc. bought a new stake in Chemours in the 4th quarter valued at $26,000. Aster Capital Management DIFC Ltd bought a new position in shares of Chemours during the 4th quarter valued at about $28,000. Covestor Ltd grew its position in shares of Chemours by 204.7% during the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock valued at $31,000 after purchasing an additional 1,748 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in shares of Chemours during the fourth quarter valued at about $31,000. Finally, Rothschild Investment LLC grew its position in shares of Chemours by 87.0% during the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock valued at $32,000 after purchasing an additional 1,255 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors.
Chemours Trading Up 0.2% CC stock opened at $17.25 on Monday. The company has a market capitalization of $2.59 billion, a PE ratio of -6.53 and a beta of 1.41. The Chemours Company has a 12 month low of $10.44 and a 12 month high of $28.67. The firm’s 50-day moving average is $20.35 and its 200 day moving average is $19.92. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87.
Chemours (NYSE:CC – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.10. The company had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $0.13 EPS. On average, research analysts anticipate that The Chemours Company will post 1.18 EPS for the current year.
Chemours Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.0%. The ex-dividend date was Friday, May 15th. Chemours’s dividend payout ratio (DPR) is presently -13.26%.
More Chemours News Here are the key news stories impacting Chemours this week:
Positive Sentiment: Zacks Research upgraded Chemours (CC) from Hold to Strong Buy, signaling stronger confidence in the company’s outlook. 3 Stocks Worth Buying After Recent Broker Ratings Upgrade Positive Sentiment: Analysts also raised longer-term earnings forecasts, including FY2028 EPS to $2.38 from $2.36, suggesting better profit potential over time. Positive Sentiment: Zacks lifted its Q4 2027 EPS estimate to $0.53 from $0.50 and increased its Q2 2028 estimate to $0.61 from $0.60, reinforcing a more constructive view on future performance. Neutral Sentiment: Chemours announced it will release second-quarter 2026 results after the market closes on August 4, which keeps investors focused on the upcoming earnings report. Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call Negative Sentiment: Zacks trimmed its Q1 2027 EPS estimate to $0.39 from $0.41 and Q3 2027 to $0.56 from $0.57, showing that not all near-term expectations are improving. Wall Street Analyst Weigh In Several brokerages recently weighed in on CC. Alembic Global Advisors restated an “overweight” rating and issued a $30.00 price target on shares of Chemours in a research report on Wednesday, May 13th. Morgan Stanley increased their price objective on shares of Chemours from $17.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research note on Friday, July 17th. UBS Group boosted their target price on shares of Chemours from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Mizuho decreased their target price on shares of Chemours from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.10.
Get Our Latest Stock Report on Chemours
Chemours Profile (Free Report)
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours’ principal business activities are organized into three core segments.
Featured Articles Five stocks we like better than Chemours RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? These 4 Earnings Reports Expose the Market’s Growing Economic Divide Broadcom May Be the Biggest Winner From Alphabet’s Earnings Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECollaborative Wealth Managment Inc. Has $744,000 Stock Position in NVIDIA Corporation $NVDA
NEXT HEADLINE »Allspring Global Investments Holdings LLC Sells 2,770 Shares of Invesco QQQ $QQQ
, /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC) today announced that the Company expects to issue its second quarter 2026 financial results after market on Tuesday, August 4, 2026.
The Company expects to hold its conference call to discuss its second quarter 2026 financial results at 8:00 a.m. Eastern Daylight Time on Wednesday, August 5, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.
Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.
Replay: A webcast replay will be available at investors.chemours.com.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of The Chemours Company (NYSE:CC – Free Report) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 170,000 shares of the specialty chemicals company’s stock, valued at approximately $3,745,000. Chemours makes up about 0.6% of Annis Gardner Whiting Capital Advisors LLC’s holdings, making the stock its 22nd largest position. Annis Gardner Whiting Capital Advisors LLC owned 0.11% of Chemours at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Cooper Creek Partners Management LLC bought a new position in shares of Chemours in the third quarter worth approximately $63,103,000. Scopia Capital Management LP boosted its holdings in Chemours by 71.7% in the 2nd quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock worth $38,418,000 after buying an additional 1,401,539 shares during the period. State Street Corp increased its stake in Chemours by 22.7% in the 2nd quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock worth $70,009,000 after buying an additional 1,131,682 shares in the last quarter. Sona Asset Management US LLC increased its stake in Chemours by 176.9% in the 4th quarter. Sona Asset Management US LLC now owns 1,651,275 shares of the specialty chemicals company’s stock worth $19,469,000 after buying an additional 1,055,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Chemours by 36.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,701,294 shares of the specialty chemicals company’s stock valued at $43,638,000 after acquiring an additional 996,012 shares during the period. 76.26% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets CC has been the subject of several recent analyst reports. Truist Financial upped their price target on Chemours from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Royal Bank Of Canada boosted their target price on shares of Chemours from $26.00 to $29.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Friday, April 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a research note on Monday, April 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Chemours from $17.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, May 21st. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Chemours presently has a consensus rating of “Hold” and a consensus price target of $24.10.
Read Our Latest Research Report on Chemours
Chemours Stock Performance NYSE:CC opened at $17.56 on Friday. The firm has a market capitalization of $2.64 billion, a PE ratio of -6.65 and a beta of 1.41. The stock’s fifty day moving average is $21.05 and its 200 day moving average is $19.67. The Chemours Company has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.87 and a current ratio of 1.82.
Chemours (NYSE:CC – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The company had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the firm earned $0.13 earnings per share. Chemours’s quarterly revenue was up 1.0% compared to the same quarter last year. On average, sell-side analysts anticipate that The Chemours Company will post 1.16 earnings per share for the current year.
Chemours Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Sunday, May 17th were given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend was Friday, May 15th. Chemours’s dividend payout ratio is -13.26%.
About Chemours (Free Report)
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours’ principal business activities are organized into three core segments.
Read More Five stocks we like better than Chemours AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECommunity Healthcare Trust (NYSE:CHCT) Now Covered by Analysts at Huntington
NEXT HEADLINE »National Healthcare Properties (NASDAQ:NHP) Coverage Initiated by Analysts at Huntington
July 01, 2026 06:03 ET | Source: Virtune AB (Publ)
Stockholm, July 1st, 2026 – Virtune today announces the completion of the rebalancing for the Virtune Stablecoin Index ETP (SE0026821282), listed on Nasdaq Stockholm, Nasdaq Helsinki and Xetra.
In addition to the Virtune Stablecoin Index ETP, Virtune’s product portfolio includes:
Index allocation as of June 30th (before rebalancing):
Ethereum: 39.30%
XRP: 23.15%
Solana: 19.40%
Stellar: 7.97%
Chainlink: 6.69%
Aave: 3.50%
Index allocation as of June 30th (after rebalancing):
Ethereum: 27.02%
BNB: 16.68%
XRP: 15.78%
Solana: 12.27%
TRON: 10.43%
Stellar: 5.05%
Canton: 4.54%
Chainlink: 4.50%
Aave: 2.01%
Ethena: 1.72%
In connection with this month's rebalancing, four new crypto assets are being added to the index: Ethena (ENA), Canton (CC), TRON (TRX), and BNB (BNB).
The index is rebalanced quarterly to reflect market changes and ensure it continues to represent the most relevant and qualitative crypto assets. The rebalancing adjusts weighting based on the square root of each crypto asset’s market capitalization and may involve removing or adding certain assets.
The performance of Virtune Stablecoin Index ETP in June was -17.87%.
Virtune Stablecoin Index ETP is a physically backed Exchange Traded Product (ETP) designed to offer investors a simple, secure, and cost-effective way to gain exposure to the expanding stablecoin ecosystem. The product tracks a diversified index of digital assets that provide the infrastructure and rails making stablecoins possible and that stand to benefit from their growing adoption and use.
If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at [email protected]. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, which cover updates on Virtune's upcoming ETP launches and other news related to digital assets.
Press contact
Christopher Kock, CEO Virtune AB (Publ) [email protected]
+46 70 073 45 64
Virtune, headquartered in Stockholm, is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.
Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.
Chemours (CC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Chemours Reaches Agreement with U.S. EPA to Resolve Claims Relating to PFAS PR Newswire
WILMINGTON, Del., June 24, 2026
The settlement resolves the federal government's claims relating to discharge of PFAS compounds across three current operating sites, as well as certain environmental claims by the State of West Virginia. Chemours is expected to pay EPA and WVDEP a $22.5 million civil penalty over a three-year period, and fund $90 million in additional mitigation projects over the next 15 years to further reduce PFAS emissions and enhance certain existing off-site drinking water programs.The settlement recognizes that Chemours has already begun planning and implementing operational improvements and remedial measures at its facilities, and contains further actions the Company will take to mitigate future emissions and enhance existing programs.This settlement provides Chemours with greater clarity on future compliance requirements and actions to support long-term responsible manufacturing., /PRNewswire/ -- The Chemours Company (NYSE: CC) (the "Company") today announced a settlement to resolve claims asserted by the U.S. Environmental Protection Agency ("EPA") relating to PFAS discharges and other alleged non-compliance actions, primarily at the Company's Washington Works, Fayetteville Works, and Chambers Works facilities. The West Virginia Department of Environmental Protection ("WVDEP") is also a party to the settlement and joins in these releases.
The settlement agreement is the latest progress delivered under the Strengthening the Long Term pillar of Chemours' Pathway to Thrive strategy, which includes the Company's sustained efforts to address legacy PFAS and other environmental claims. The settlement also recognizes the significant work already completed or underway across Chemours' sites to reduce emissions and strengthen processes.
Under the settlement, Chemours has agreed to pay EPA and WVDEP a $22.5 million civil penalty, of which $15 million was previously accrued. This civil penalty is expected to be paid in three annual installments in 2026, 2027 and 2028, beginning within 30 days of the court's approval of the Consent Decree containing the settlement. In addition, over the next 15 years, Chemours will fund $90 million in additional mitigation projects to further reduce PFAS emissions from the operating sites or drinking water projects. Such projects support Chemours responsible manufacturing practices and will help advance the Company's Corporate Responsibility Commitment goal to reduce process emissions of fluorinated organic chemicals by 99% or more by 2030.
Further, the Company has also agreed to perform certain program and site-related actions as part of the settlement. This includes an expansion of the Company's existing off-site drinking water programs in West Virginia, Ohio, and New Jersey to incorporate learnings from Chemours' other off-site programs. The Company expects the expansion of the off-site drinking water programs will result in an increase to its existing environmental reserves.
Aligned with the Company's Pathway to Thrive strategy, Chemours continues to focus on responsibly resolving outstanding environmental and regulatory matters with terms that improve site operating certainty and include payment and remediation commitments that are structured over time. The terms of the settlement, including a further description of claims released and not released, are set forth in a proposed Consent Decree, which remains subject to final court approval.
In connection with the settlement, Chemours has also reached a resolution with the West Virginia Rivers Coalition for less than $1 million to resolve its litigation that was commenced in 2024 under the Clean Water Act alleging exceedances of certain permitted discharge limits at the Company's Washington Works facility.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the expected performance and impact of the cost-sharing arrangements by and between Chemours, Corteva and DuPont related to future eligible PFAS liabilities. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome of the final court approval process for the Consent Decree, including any appeals, the outcome of any pending or future litigation related to PFAS or PFOA, including personal injury claims and natural resource damages claims, the extent and cost of ongoing remediation obligations and potential future remediation obligations, including performance of injunctive actions and mitigation projects under the Consent Decree, changes in laws and regulations applicable to PFAS chemicals, the performance by each of the parties of their respective obligations under the cost-sharing arrangement, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, Chemours' ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of the Company's products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for the Company's segments individually and the Company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, the Company's ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, the Company's ability to make acquisitions, integrate acquired businesses or assets into the Company's operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond the Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect the Company's business and operations and may or may continue to hinder the Company's ability to provide goods and services to customers, cause disruptions in the Company's supply chains such as through strikes, labor disruptions or other events, adversely affect the Company's business partners, significantly reduce the demand for the Company's products, adversely affect the health and welfare of the Company's personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that the Company is unable to identify at this time or that the Company does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309 [email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140 [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-reaches-agreement-with-us-epa-to-resolve-claims-relating-to-pfas-302809444.html
The settlement resolves the federal government's claims relating to discharge of PFAS compounds across three current operating sites, as well as certain environmental claims by the State of West Virginia. Chemours is expected to pay EPA and WVDEP a $22.5 million civil penalty over a three-year period, and fund $90 million in additional mitigation projects over the next 15 years to further reduce PFAS emissions and enhance certain existing off-site drinking water programs. The settlement recognizes that Chemours has already begun planning and implementing operational improvements and remedial measures at its facilities, and contains further actions the Company will take to mitigate future emissions and enhance existing programs. This settlement provides Chemours with greater clarity on future compliance requirements and actions to support long-term responsible manufacturing. , /PRNewswire/ -- The Chemours Company (NYSE: CC) (the "Company") today announced a settlement to resolve claims asserted by the U.S. Environmental Protection Agency ("EPA") relating to PFAS discharges and other alleged non-compliance actions, primarily at the Company's Washington Works, Fayetteville Works, and Chambers Works facilities. The West Virginia Department of Environmental Protection ("WVDEP") is also a party to the settlement and joins in these releases.
The settlement agreement is the latest progress delivered under the Strengthening the Long Term pillar of Chemours' Pathway to Thrive strategy, which includes the Company's sustained efforts to address legacy PFAS and other environmental claims. The settlement also recognizes the significant work already completed or underway across Chemours' sites to reduce emissions and strengthen processes.
Under the settlement, Chemours has agreed to pay EPA and WVDEP a $22.5 million civil penalty, of which $15 million was previously accrued. This civil penalty is expected to be paid in three annual installments in 2026, 2027 and 2028, beginning within 30 days of the court's approval of the Consent Decree containing the settlement. In addition, over the next 15 years, Chemours will fund $90 million in additional mitigation projects to further reduce PFAS emissions from the operating sites or drinking water projects. Such projects support Chemours responsible manufacturing practices and will help advance the Company's Corporate Responsibility Commitment goal to reduce process emissions of fluorinated organic chemicals by 99% or more by 2030.
Further, the Company has also agreed to perform certain program and site-related actions as part of the settlement. This includes an expansion of the Company's existing off-site drinking water programs in West Virginia, Ohio, and New Jersey to incorporate learnings from Chemours' other off-site programs. The Company expects the expansion of the off-site drinking water programs will result in an increase to its existing environmental reserves.
Aligned with the Company's Pathway to Thrive strategy, Chemours continues to focus on responsibly resolving outstanding environmental and regulatory matters with terms that improve site operating certainty and include payment and remediation commitments that are structured over time. The terms of the settlement, including a further description of claims released and not released, are set forth in a proposed Consent Decree, which remains subject to final court approval.
In connection with the settlement, Chemours has also reached a resolution with the West Virginia Rivers Coalition for less than $1 million to resolve its litigation that was commenced in 2024 under the Clean Water Act alleging exceedances of certain permitted discharge limits at the Company's Washington Works facility.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the expected performance and impact of the cost-sharing arrangements by and between Chemours, Corteva and DuPont related to future eligible PFAS liabilities. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome of the final court approval process for the Consent Decree, including any appeals, the outcome of any pending or future litigation related to PFAS or PFOA, including personal injury claims and natural resource damages claims, the extent and cost of ongoing remediation obligations and potential future remediation obligations, including performance of injunctive actions and mitigation projects under the Consent Decree, changes in laws and regulations applicable to PFAS chemicals, the performance by each of the parties of their respective obligations under the cost-sharing arrangement, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, Chemours' ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of the Company's products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for the Company's segments individually and the Company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, the Company's ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, the Company's ability to make acquisitions, integrate acquired businesses or assets into the Company's operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond the Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect the Company's business and operations and may or may continue to hinder the Company's ability to provide goods and services to customers, cause disruptions in the Company's supply chains such as through strikes, labor disruptions or other events, adversely affect the Company's business partners, significantly reduce the demand for the Company's products, adversely affect the health and welfare of the Company's personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that the Company is unable to identify at this time or that the Company does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
, /PRNewswire/ -- Canton Strategic Holdings, Inc. (NASDAQ: CNTN) ("Canton Strategic Holdings" or the "Company"), the first publicly traded company to leverage Canton Coin (CC) to support the Canton Network's ability to digitize traditional financial markets, today announced it is expected to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index following the semi-annual reconstitution, effective after market close on June 26, 2026, according to a preliminary list of additions published by FTSE Russell.
"As the only company providing active equity exposure to the Canton Network ecosystem, we are proud to be considered for inclusion in the Russell 3000® and Russell 2000®, including their respective value and growth indices," said Mark Wendland, Chairman and Chief Executive Officer of Canton Strategic Holdings. "This distinction reflects the strength of our Canton-aligned strategy and our ability to deliver on behalf of a broader set of investors while supporting the Canton Network's modernization of financial rails."
The semi-annual reconstitution of the Russell indices evaluates companies by market cap as well as style. The current reconstitution was conducted with data as of April 30, 2026.
About Canton Strategic Holdings, Inc.
Canton Strategic Holdings, Inc. (NASDAQ: CNTN) is the first publicly traded company to leverage Canton Coin and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network, the Company also operates clinical-stage biotech research and development. For more information, visit www.cantonstrategic.com.
This press release contains statements that constitute "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are statements other than historical facts and include, without limitation, those regarding management expectations, strategy execution, market conditions, and the Company's involvement with the Canton Network. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Further information regarding factors that may affect the Company's prospects is included in its annual and quarterly reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov. The Company undertakes no obligation to update these statements except as required by law.
Canton is a registered trademark of Digital Asset (Switzerland) GmbH. Digital Asset is not affiliated with, and has not sponsored or endorsed, the operations of Canton Strategic Holdings, Inc.
, /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC) today announced it completed its previously announced private offering of $700,000,000 in aggregate principal amount of 7.875% senior unsecured notes due 2034 (the "Notes") that was exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The Notes are Chemours' senior unsecured obligations and are guaranteed by one of its subsidiaries.
Chemours used the net proceeds from the offering, together with cash on hand, to fund the redemption of $188,000,000 aggregate principal amount of its 5.750% senior notes due 2028 for an aggregate redemption price of approximately $189,800,000, plus accrued and unpaid interest thereon. The remaining net proceeds from the offering are expected to be used to fund the redemption of the outstanding 5.375% senior notes due 2027 for an aggregate redemption price of approximately $500,300,000 in (assuming a treasury rate of 3.56%), plus accrued and unpaid interest to, but excluding, the date of redemption.
The Notes and the related guarantee have not been, and will not be, registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. The Notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons in accordance with Regulation S under the Securities Act.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not an offer to purchase or the solicitation of an offer to sell any of the existing 2027 or 2028 notes. The statements in this press release with respect to the redemption of the existing 2027 or 2028 notes do not constitute a notice of redemption under the indenture governing the existing 2027 or 2028 notes, as applicable. Any such notice has or will be sent to holders of existing 2027 and 2028 notes only in accordance with the provisions of each such indenture, as applicable.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements address, among other things, Chemours' intended use of the net proceeds therefrom, including the expectation to redeem all of the outstanding existing 2027 notes. Forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the redemption of the existing 2027 notes and other risks, uncertainties and other factors discussed in Chemours' filings with the U.S. Securities and Exchange Commission, including in Chemours' Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
The Chemours Company (NYSE: CC - Get Free Report) saw some unusual options trading activity on Friday. Stock investors purchased 10,642 call options on the company. This is an increase of 182% compared to the typical volume of 3,771 call options. Chemours Stock Performance Shares of CC stock opened at $17.60 on Friday. Chemours has a
The article analyzes the Canton Network and its CIP-0105 update, which incentivizes Super Validators to lock rewards, aligning interests with long-term network success. CIP-0105 could result in 20–32% of Canton Coin supply being locked over the long run, reducing circulating supply and disincentivizing opportunistic selling. Major financial institutions like Nasdaq, DTCC, and others serve as Super Validators, signaling strong institutional adoption and potential for network effects.
SG Americas Securities LLC grew its position in The Chemours Company (NYSE:CC – Free Report) by 478.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 236,236 shares of the specialty chemicals company’s stock after purchasing an additional 195,393 shares during the quarter. SG Americas Securities LLC owned about 0.16% of Chemours worth $2,785,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in CC. Wealth Enhancement Advisory Services LLC lifted its holdings in Chemours by 57.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 20,691 shares of the specialty chemicals company’s stock worth $244,000 after purchasing an additional 7,511 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Chemours during the 3rd quarter worth $1,925,000. Penn Capital Management Company LLC bought a new position in Chemours during the 3rd quarter worth $10,325,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Chemours during the third quarter worth $254,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Chemours in the third quarter valued at about $43,000. Institutional investors own 76.26% of the company’s stock.
Analyst Ratings Changes A number of research firms recently commented on CC. BMO Capital Markets lowered their price target on shares of Chemours from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Monday, February 23rd. Morgan Stanley boosted their price objective on shares of Chemours from $15.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 23rd. Mizuho increased their target price on shares of Chemours from $17.00 to $21.00 and gave the stock an “outperform” rating in a research report on Thursday, March 5th. Jefferies Financial Group reaffirmed a “hold” rating and set a $17.00 target price on shares of Chemours in a report on Monday, February 23rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $18.00 price target on shares of Chemours in a research note on Friday, January 16th. Five equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Chemours presently has a consensus rating of “Hold” and a consensus target price of $18.40.
Check Out Our Latest Research Report on CC
Chemours Price Performance Shares of NYSE:CC opened at $21.56 on Friday. The firm has a 50 day moving average of $18.58 and a 200-day moving average of $15.29. The Chemours Company has a 12 month low of $9.13 and a 12 month high of $22.43. The company has a current ratio of 1.78, a quick ratio of 0.85 and a debt-to-equity ratio of 16.33. The stock has a market capitalization of $3.24 billion, a PE ratio of -8.69 and a beta of 1.41.
Chemours (NYSE:CC – Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.04. Chemours had a negative net margin of 6.41% and a positive return on equity of 41.75%. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter last year, the business posted $0.09 EPS. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. On average, equities research analysts predict that The Chemours Company will post 2.03 EPS for the current fiscal year.
Chemours Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Friday, March 13th. Shareholders of record on Friday, February 27th were given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date was Friday, February 27th. Chemours’s payout ratio is currently -14.11%.
Chemours Profile (Free Report)
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours’ principal business activities are organized into three core segments.
Featured Stories Five stocks we like better than Chemours
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
On April 10, 2026, The Chemours Co CC shares experienced a notable increase of 4.0% today, bringing the current price to $22.71. This price movement is significant when considering the stock's 52-week range, which has seen a low of $9.13 and a high of $22.99.
GF Value™ verdict: The current price of $22.71 is 9.2% above the GF Value™ estimate of $20.79, indicating the stock is overvalued.GF Score™: With a score of 74/100, Chemours is rated as above average based on key financial metrics.Most notable signal: The momentum rank is strong at 10/10, suggesting robust price performance in recent periods. Is CC Overvalued or Undervalued? The current price of The Chemours Co CC at $22.71 is above the GF Value™ estimate of $20.79, which implies that the stock is overvalued by approximately 9.2%. This overvaluation indicates a lack of margin of safety for potential investors, as shares trading above their intrinsic value can signify heightened risk. The GF Valuation label categorizes the stock as fairly valued, but this assessment must be taken with caution given its current pricing dynamics.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Being overvalued suggests that investors may face risks if the stock does not meet growth expectations moving forward, or if market conditions shift unfavorably.
How Does CC's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 15.9x 13.2x The current P/E of 15.9x is above the 5-year median P/E of 13.2x, indicating that Chemours is trading at a higher valuation compared to its historical average. This aligns with the GF Value™ conclusion that the stock is currently overvalued, as the elevated P/E suggests that the stock may be priced for growth that could be challenging to achieve.
What Does CC's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Higher GF Score™ values are associated with higher long-term returns, as evidenced by backtesting from 2006 to 2021.
Metric Rating GF Score™ 74 Financial Strength 3/10 Profitability 6/10 Growth 4/10 Valuation 7/10 Momentum 10/10 The GF Score™ of 74/100 suggests that Chemours has a solid standing relative to its peers, with particularly strong momentum (10/10) indicating positive price movements in recent times. However, the financial strength score of 3/10 is notably weak, suggesting potential vulnerabilities in the company's financial health. Profitability and growth ranks are average, indicating room for improvement in these areas.
What Are Insiders Doing with CC Stock? In the last three months, there have been no insider transactions reported for The Chemours Co CC . This lack of activity may suggest that insiders are not currently making significant stock moves, which could imply confidence in the company's stability or a wait-and-see approach regarding the stock's valuation.
What This Means for Investors Based on the analysis of GF Value™, The Chemours Co CC appears to be overvalued at its current price of $22.71 relative to the intrinsic value estimated at $20.79. This situation may present risks for potential investors as the stock is trading above its fair value, highlighting the importance of conducting thorough due diligence before making any investment decisions.
For the complete analysis, visit the The Chemours Co CC stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is CC's GF Score™?
The GF Score™ for The Chemours Co CC is 74/100, indicating an above-average rating based on several key financial metrics.
Is CC overvalued or undervalued?
CC is currently overvalued as its price of $22.71 exceeds the GF Value™ estimate of $20.79, indicating a 9.2% overvaluation.
What is CC's P/E ratio?
The current P/E ratio for The Chemours Co CC is 15.9x, which is above its historical 5-year median P/E of 13.2x, confirming the stock's overvaluation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
, /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC) today announced that the Company expects to issue its first quarter 2026 financial results after market on Tuesday, May 5, 2026.
The Company expects to hold its conference call to discuss its first quarter 2026 financial results at 8:00 a.m. Eastern Time on Wednesday, May 6, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.
Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.
Replay: A webcast replay will be available at investors.chemours.com.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
On April 23, 2026, Hasbro Inc HAS released its 8-K filing detailing preliminary first-quarter 2026 results and operational updates. The company expects Q1 revenue in the range of $970 million to $985 million, supported by “continued strength in MAGIC: THE GATHERING,” and operating profit of $235 million to $245 million. Hasbro Inc (HAS) plans to report full first-quarter results before the market open on May 20, 2026.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to 19 million digital tabletop players.
Preliminary Q1 2026 highlights and estimate comparison Preliminary Q1 revenue of $970 million to $985 million is above the analyst estimated revenue of $908.86 million. Revenue growth is expected to be up 9% to 11% year over year.
Operating profit of $235 million to $245 million implies year-over-year growth of 38% to 44%. Adjusted operating profit of $250 million to $260 million implies year-over-year growth of 12% to 17%.
Management reiterated full-year 2026 guidance for total revenue growth of 3% to 5% in constant currency, adjusted operating margin of 24% to 25%, and adjusted EBITDA of $1.40 billion to $1.45 billion.
Metric Q1 2026 Preliminary (Low) Q1 2026 Preliminary (High) YoY Change Analyst Estimate (if applicable) Revenue $970M $985M +9% to +11% $908.86M Operating Profit $235M $245M +38% to +44% N/A Adjusted Operating Profit $250M $260M +12% to +17% N/A 2026 Guidance (reiterated) Total Revenue Growth (CC) +3% +5% N/A N/A Adjusted Operating Margin 24% 25% N/A N/A Adjusted EBITDA $1.40B $1.45B N/A N/AOperational update and risks Hasbro disclosed progress on a previously announced cybersecurity event. According to the filing,
the Company believes that the unauthorized access has been contained and the Company is making progress in fully restoring its systems and operations.The company added,
This unauthorized access did not impact the Company’s financial results for the first quarter.While core trading-card shipments have proceeded, the company noted,
MAGIC: THE GATHERING shipments and its release cadence have continued as planned in the second quarter, including the April 2026 release of Secrets of Strixhaven.For the Consumer Products segment, Hasbro expects temporary operational frictions in Q2 due to order processing, shipping, and invoicing delays, stating,
the majority of any delayed shipping in the second quarter will be made up in the back-half of 2026.The company also said,
The second quarter is also expected to contain certain investigatory and other advisor costs related to the unauthorized access.Hasbro plans to release full Q1 results and host its earnings call on Wednesday, May 20, 2026, at 8:30 a.m. ET. The webcast and slides will be available at investor.hasbro.com.
Financial achievements and why they matter Top-line growth of 9% to 11% alongside operating profit growth of 38% to 44% signals positive operating leverage, led by the performance of MAGIC: THE GATHERING. For a company in the broader Travel & Leisure ecosystem—where discretionary spend and brand engagement are critical—this combination underscores the importance of resilient, high-margin franchises to buffer cyclicality and support reinvestment.
Adjusted operating profit of $250 million to $260 million is particularly relevant for investors evaluating underlying operations independent of non-recurring items such as acquired intangible amortization and restructuring. The company provided a detailed reconciliation indicating non-GAAP adjustments for acquired intangible amortization ($10 million), strategic transformation initiatives ($1 million), and restructuring and severance costs ($5 million).
Income statement, balance sheet, and cash flow context The press release provides preliminary income statement indicators—revenue, operating profit, and adjusted operating profit—but does not include full financial statements. These metrics are central to assessing near-term profitability and operating efficiency heading into the key mid-year product cycle. Adjusted EBITDA guidance of $1.40 billion to $1.45 billion offers a cash earnings proxy that is closely watched across the leisure and branded entertainment space for its correlation with investment capacity and debt serviceability.
While detailed balance sheet and cash flow data are pending the full Q1 release, operating margin targets of 24% to 25% inform expectations for capital allocation flexibility. Stronger margins in branded IP-driven businesses often translate into higher free cash flow conversion, which can support product development, marketing, and selective licensing opportunities across the portfolio.
Commentary excerpts The filing emphasized the growth driver and nature of the results and disclosure:
Hasbro, Inc. (NASDAQ: HAS), a leading games, IP and toy company, today announced preliminary results for the first quarter ended March 29, 2026, with growth behind continued strength in MAGIC: THE GATHERING.The unaudited financial information presented in this press release is preliminary and may change.Analysis Preliminary revenue above consensus points to sustained momentum in MAGIC: THE GATHERING and a favorable mix, with operating leverage evident in the profit ranges. The reiterated full-year targets suggest confidence in execution despite temporary operational disruptions tied to the cybersecurity event.
Key challenges include the anticipated Q2 timing impacts in Consumer Products and incremental advisory costs. These may weigh on near-term reported results. However, the company indicates order flow and shipments are expected to normalize later in the year, which could mitigate revenue timing pressures.
GuruFocus Valuation Check Based on GuruFocus’ proprietary GF Value framework, Hasbro Inc HAS appears overvalued. The GF Value is $62.25 versus a current price of $90.61, indicating shares trade at approximately 45.6% above the estimated fair value.
The GF Score of 72/100 is considered above average, suggesting a balanced but not exceptional overall investment profile. A Profitability Rank of 7/10 indicates solid earnings quality and margins relative to peers. A Financial Strength score of 5/10 points to a moderate balance sheet and leverage position. The Growth Rank of 3/10 and Predictability of 1 star signal lower visibility into consistent expansion or repeatability of results, which can introduce variability in outcomes. A Moat Score of 6/10 reflects a competitive position supported by notable brands and IP, but not an unassailable advantage.
Insiders have sold $42.9 million worth of shares over the past three months, with no reported insider buying. Large net insider selling can be a cautionary signal for investors monitoring alignment and sentiment. For a deeper dive, visit the Hasbro Inc stock page on GuruFocus.
Explore the complete 8-K earnings release (here) from Hasbro Inc for further details.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
VICTORIA, Seychelles, April 24, 2026 (GLOBE NEWSWIRE) -- Bitget, the world’s largest Universal Exchange (UEX), announced the addition of Canton (CC) to Bitget Launchpool and spot market. Spot trading for the CC/USDT pair opens on April 24, 2026, 10:00 (UTC), with withdrawals available from April 25, 2026, 10:00 (UTC).
To celebrate the listing, Bitget Launchpool will run a campaign offering 1,800,000 CC in rewards. Eligible users can participate by locking BGB, USDGO, and CC during the event, which runs from April 24, 2026, 10:00 (UTC) till May 1, 2026, 10:00 (UTC). In the BGB locking pool, users can lock between 5 BGB and 50,000 BGB, with maximum limits determined by their VIP tier, to share a prize pool of 1,540,000 CC. In the USDGO locking pool, users can look between 50 USDGO and 500,000 USDGO for a share of 130,000 CC. In the CC locking pool, users can lock between 300 and 3,000,000 CC for a share of 130,000 CC in rewards. Token airdrops from Launchpool locking pools will be distributed hourly based on each participant's locked volume.
Canton Network is a privacy-focused Layer 1 blockchain protocol engineered to provide interoperable infrastructure for institutional finance and real-world asset tokenization. By utilizing the Daml smart contract language, the architecture ensures data confidentiality where transaction details remain visible only to authorized stakeholders, fulfilling the rigorous privacy requirements of regulated global markets. This decentralized framework enables the atomic settlement of diverse digital assets, such as tokenized bonds and deposits, across disparate institutional systems without relying on vulnerable cross-chain bridges or traditional intermediaries.
The protocol streamlines capital mobility by consolidating isolated financial silos into a unified, secure environment for 24/7 on-chain execution. This high-density connectivity ultimately enhances global liquidity and enables institutions to manage complex portfolios with increased speed and precision while maintaining total data integrity.
Bitget’s Universal Exchange (UEX) combines exchange grade infrastructure with OnChain access, giving users a single account to discover and trade millions of tokens across leading networks. While this open gateway enables broad market access without traditional listing bottlenecks, Bitget’s listing highlights a different tier of assets—projects with real backing, clear utility, strong community and partner support. Together, UEX offers both breadth and quality: universal discovery at scale, and curated opportunities for users who prefer to explore crypto's vastness. The addition of Canton (CC) further enhances these opportunities, reinforcing Bitget’s role in bridging the gap between regulated financial instruments and crypto-native innovation.
For more details on Canton (CC) and the promotion, visit here.
About Bitget
Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 100+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships with LALIGA and MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.
For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord
Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c3feaccd-8ac7-49b3-97b4-25e547a27d78
, /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the first quarter 2026.
Key First Quarter 2026 Results & Recent Highlights1
Net Sales of $1.4 billion, slightly up compared to the corresponding prior-year quarter, with TSS reporting record first quarter results, with continued double-digit year-over-year sales growth in Opteon™ Refrigerants Net Loss attributable to Chemours of $29 million, or $0.19 per diluted share, compared with Net Loss attributable to Chemours of $5 million, or $0.03 per diluted share, in the corresponding prior-year quarter Adjusted Net Income2 of $8 million, or $0.05 per diluted share, compared to Adjusted Net Income of $19 million, or $0.13 per diluted share, in the corresponding prior-year quarter Adjusted EBITDA2,3 of $169 million compared to $166 million in the corresponding prior-year quarter Announced a global TiO2 price increase effective April 1, 2026, as a continuation of our December price actions; achieved a sequential TiO2 price increase of 3% in Net Sales Received ~$287 million initial net proceeds from the sale of the Kuan Yin site, positioning the Company to paydown €140 million of outstanding debt "Chemours exceeded overall expectations in the first quarter, achieving strong outcomes from both our TSS and TT businesses, paired with the more recent receipt of cash through the completion of a substantial portion of our Kuan Yin property sales enabling us to reduce our debt," stated Denise Dignam, Chemours President and CEO. "These achievements demonstrate our dedication to our Pathway to Thrive strategy and highlight the importance we place on effective execution. While the wider economic landscape remains uncertain, Chemours continues to drive full-year growth while remaining steadfast in prioritizing flexible commercial and operational strategies to ensure Chemours is able to capitalize on opportunities in our key markets."
Total Chemours
Q1 2026
Q1 2025
Y-o-Y % ∆
Q4 2025
Q-o-Q % ∆
Net Sales (millions)
$1,381
$1,368
1 %
$1,329
4 %
Net Loss (millions)
($29)
($5)
(480 %)
($47)
38 %
Loss Per Share4
($0.19)
($0.03)
(533 %)
($0.31)
39 %
Adjusted Net Income
$8
$19
(58 %)
$7
14 %
Adjusted EPS
$0.05
$0.13
(62 %)
$0.05
0 %
Adjusted EBITDA (millions)
$169
$166
2 %
$128
32 %
First quarter 2026 Net Sales were $1.4 billion, an increase of 1% compared to the prior-year quarter. Reported Net Sales were primarily driven by a 2% increase in price and a 3% increase in currency, partially offset by a 4% decrease in volumes. The overall increase in price was driven by automotive Freon™ pricing for TSS in North America, partially offset by TT and APM. The decrease in volume was primarily driven by constraints in production due to an operational outage in APM and weaker cyclical end markets impacting both TT and APM, partially offset by continued strength in TSS volume tied to increased Opteon™ Refrigerants adoption and Freon™ sales.
First quarter 2026 Net Loss attributable to Chemours was $29 million, or $0.19 per diluted share, compared to Net Loss attributable to Chemours of $5 million, or $0.03 per diluted share in the prior-year quarter. The larger first quarter Net Loss attributable to Chemours was driven by increased financing costs associated with a recent debt offering and higher Selling, General and Administrative costs. Adjusted EBITDA for the first quarter of 2026 was $169 million, compared to $166 million in the prior-year quarter with the referenced higher pricing, currency and other income more than offsetting overall higher costs paired with lower sales volumes in APM and TT.
Thermal & Specialized Solutions
Q1 2026
Q1 2025
Y-o-Y % ∆
Q4 2025
Q-o-Q % ∆
Net Sales (millions)
$568
$466
22 %
$444
28 %
Opteon™ Refrigerants
$313
$279
12 %
$243
29 %
Freon™ Refrigerants
$162
$97
67 %
$113
43 %
Foam, Propellants & Other (FP&O)
$93
$90
3 %
$87
7 %
Adjusted EBITDA (millions)
$190
$141
35 %
$128
48 %
Adjusted EBITDA Margin
33 %
30 %
3 ppts
29 %
4 ppts
For the first quarter of 2026, TSS segment results reflected both record sales, inclusive of a 12% year-over-year growth in Opteon™ Refrigerants, and Adjusted EBITDA.
TSS segment first quarter 2026 Net Sales were $568 million, an increase of 22% versus the prior‑year quarter, driven by an 11% increase in price and a 9% increase in volume, with a 2% currency tailwind. Increased pricing was primarily driven by automotive Freon™ Refrigerant sales in North America. Volume growth was driven by the continued transition to Opteon™ Refrigerants as well as automotive Freon™ Refrigerant sales in North America.
Adjusted EBITDA for the quarter increased 35% to $190 million, while Adjusted EBITDA Margin increased three points to 33%. The increase in Adjusted EBITDA was driven by higher pricing associated with the referenced automotive Freon™ sales and a transition to a more favorable product mix in Opteon™ Refrigerant blends, partially offset by higher input costs associated with R32, a key component of our stationary Opteon™ Refrigerant blends, in the quarter.
Sequentially, Net Sales increased 28%, driven by a 22% seasonal volume increase supported by a 6% pricing increase. Volumes followed seasonal patterns, increasing across all refrigerants.
Titanium Technologies
Q1 2026
Q1 2025
Y-o-Y % ∆
Q4 2025
Q-o-Q % ∆
Net Sales (millions)
$559
$597
(6 %)
$561
(0 %)
TiO2 Pigment
$541
$575
(6 %)
$534
1 %
Minerals
$18
$22
(18 %)
$27
(33 %)
Adjusted EBITDA (millions)
$18
$50
(64 %)
$23
(22 %)
Adjusted EBITDA Margin
3 %
8 %
(5) ppts
4 %
(1) ppts
TT segment first quarter 2026 Net Sales were $559 million, a 6% decrease compared to the prior-year quarter. This decrease was the result of a 7% decline in volumes globally, with favorable currency of 3% more than offsetting lower pricing of 2%. The decrease in volumes was driven by lower TiO2 sales concentrated in North America and certain non-western markets, which also negatively impacted product mix.
TT segment first quarter 2026 Adjusted EBITDA decreased 64% to $18 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased five percentage points to 3%. The decline in Adjusted EBITDA was primarily driven by the decline in sales as well as an unfavorable ore mix with Q1 production paired with decisions to adjust TT's mining footprint.
Sequentially, TT segment first quarter 2026 Net Sales were approximately flat, with a 3% increase in price, reflective of pricing actions announced in the fourth quarter of 2025, offset by a 3% decrease in volume.
Advanced Performance Materials
Q1 2026
Q1 2025
Y-o-Y % ∆
Q4 2025
Q-o-Q % ∆
Net Sales (millions)
$243
$294
(17 %)
$312
(22 %)
Advanced Materials
$143
$178
(20 %)
$172
(17 %)
Performance Solutions
$100
$116
(14 %)
$141
(29 %)
Adjusted EBITDA (millions)
$5
$32
(84 %)
$12
(58 %)
Adjusted EBITDA Margin
2 %
11 %
(9) ppt
4 %
(2) ppts
APM segment first quarter 2026 Net Sales were $243 million, a 17% decrease compared to the prior-year quarter. This decrease was primarily driven by a 19% decrease in volume with favorable currency of 3% further offsetting a 1% decrease in price. The volume decline was primarily driven by sales constraints due to the Washington Works plant outage in Q1 and recent closure of APM's Advanced Materials SPS Capstone™ line, completed in the third quarter of 2025.
APM segment first quarter 2026 Adjusted EBITDA decreased 84% to $5 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased nine percentage points to 2%. The decrease in Adjusted EBITDA was primarily driven by the referenced lower sales volumes and related additional costs from the outage which combined for approximately $25 million for the quarter.
Sequentially, APM segment first quarter 2026 Net Sales were down approximately 22%, driven by a 22% decrease in volumes, related to decreased volumes across both Performance Solutions and Advanced Materials. The decline in volumes was due to the referenced first quarter Washington Works outage as well as contractual sales timing.
Other Non-Reportable Segment
The Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the first quarter 2026 of $11 million and $3 million, respectively.
Corporate Expenses
Corporate Expenses were $47 million in the first quarter of 2026, a decrease of approximately $10 million compared to the prior-year quarter. This was primarily due to lower costs associated with legacy litigation activities.
Liquidity and Capital Allocation
As of March 31, 2026, consolidated gross debt was $4.2 billion5. Debt, net of $563 million in unrestricted cash and cash equivalents, was $3.6 billion, resulting in a net leverage ratio of approximately 4.9x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.5 billion, comprised of $563 million in unrestricted6 cash and cash equivalents and $953 million of revolving credit facility capacity, net of outstanding letters of credit.
In April 2026, the Company completed the sale of nine of the ten parcels of land at the Company's Kuan Yin site which are classified as held-for-sale and received net cash proceeds of approximately $287 million. The sale of the tenth parcel of land is expected to be completed by the end of 2026 for a remaining gross purchase price of approximately $55 million. Using part of the initial cash proceeds received, as well as cash on hand, in April 2026, the Company paid down €140 million of the outstanding tranche B-3 Euro Term loans due August 2028. The Company expects further debt repayments in 2026.
Operating cash usage for the first quarter of 2026 was $44 million, compared to a usage of $112 million in the prior-year quarter highlighting improvements in net working capital performance.
Capital expenditures for the first quarter of 2026 amounted to $49 million, a decrease in spend compared to $84 million in the prior-year quarter, driven by lower capital expenditures in TSS.
Free Cash Flows for the first quarter of 2026 reflected a usage of $93 million, compared to a usage of $196 million in the first quarter of 2025.
Second Quarter 2026 Outlook
In the second quarter, the Company anticipates consolidated Net Sales to increase in the range of 15% to 20%, sequentially, driven by favorable seasonal trends, with consolidated Adjusted EBITDA expected to range between $220 million and $250 million. Corporate Expenses are expected to approximate $45 million to $50 million. The Company also anticipates capital expenditures to approximate $50 million, with Free Cash Flows of at least $100 million.
TSS projects Net Sales will sequentially increase in the low-to-mid teens percentage range, driven by seasonality in connection with the 2026 cooling season in the northern hemisphere with strength in both Freon™ and Opteon™ Refrigerants. Adjusted EBITDA is expected to be between $210 million and $225 million.
TT expects an overall sequential Net Sales increase in the mid-to high teens percentage range, driven by seasonal volume strength and a favorable mix for TiO2 pigment, supported by recent pricing actions, paired with increased minerals sales. Adjusted EBITDA is expected to range between $40 million and $50 million.
APM expects a sequential Net Sales increase in the low-to-high thirties percentage range, driven by a return to normal operating levels at the Washington Works facility while reflecting some limited residual impacts from the outage. Adjusted EBITDA for APM is expected to be between $12 million and $18 million.
Full Year 2026 Outlook
The Company continues to expect 2026 Net Sales to grow in the range of 3% to 5% over 2025, with Adjusted EBITDA between $800 million and $900 million. This outlook is supported by higher TSS and APM Performance Solutions demand, anticipated TT pricing momentum, and ongoing cost improvements in each business. Capital expenditures are anticipated to be between $275 million and $325 million, with overall Free Cash Flow Conversion above 20%, due to increased earnings and improvements in working capital throughout the year. This revised estimate now reflects the approximate $30 million estimated full year income tax cash outflow related to the expected proceeds to be distributed on the sale of land at the former Kuan Yin TiO2 site. As an update to previous expectations, the Company anticipates that these cash flow dynamics will produce a net leverage ratio of less than 3.8x by the end of 2026.
Conference Call
As previously announced, Chemours will hold a conference call and webcast on May 6, 2026, at 8:00 AM Eastern Time. The webcast and materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours' investor website.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.
Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2026, the full year 2026 and the Company's corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
1
Certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Annual Report on Form 10-K for the year ended December 31, 2025.
2
Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".
3
Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.
4
On a diluted earnings per share basis.
5
This amount does not reflect the €140 million used to reduce outstanding debt, which occurred in April of 2026.
6
Restricted cash approximated $53 million of the end of the first quarter of 2026, reflecting primarily escrow payments Chemours has made related to the MOU agreement with DuPont, Corteva and EID as further described in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
The Chemours Company
Consolidated Statements of Operations (Unaudited)1
(Dollars in millions, except per share amounts)
Three Months Ended March 31,
2026
2025
Net sales
$
1,381
$
1,368
Cost of goods sold
1,169
1,132
Gross profit
212
236
Selling, general, and administrative expense
147
123
Research and development expense
26
27
Restructuring, asset-related, and other charges
13
33
Total other operating expenses
186
183
Equity in earnings of affiliates
8
8
Interest expense, net
(69)
(66)
Loss on extinguishment of debt
(9)
—
Other income, net
22
5
Loss before income taxes
(22)
—
Provision for income taxes
7
5
Net loss
(29)
(5)
Net loss attributable to Chemours
$
(29)
$
(5)
Per share data
Basic (loss) earnings per share of common stock
$
(0.19)
$
(0.03)
Diluted (loss) earnings per share of common stock
(0.19)
(0.03)
The Chemours Company
Consolidated Balance Sheets (Unaudited)1
(Dollars in millions, except per share amounts)
March 31, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
563
$
670
Restricted cash and restricted cash equivalents
—
2
Accounts and notes receivable, net
759
679
Inventories
1,536
1,569
Prepaid expenses and other
69
80
Assets held for sale
1
1
Total current assets
2,928
3,001
Property, plant, and equipment
9,925
9,920
Less: Accumulated depreciation
(6,885)
(6,842)
Property, plant, and equipment, net
3,040
3,078
Operating lease right-of-use assets
274
271
Goodwill
46
46
Other intangible assets, net
2
2
Investments in affiliates
166
160
Assets held for sale, non-current
21
21
Restricted cash and restricted cash equivalents
52
52
Other assets
738
751
Total assets
$
7,267
$
7,382
Liabilities
Current liabilities:
Accounts payable
$
891
$
954
Compensation and other employee-related cost
122
96
Short-term and current maturities of long-term debt
37
42
Current environmental remediation
97
88
Other accrued liabilities
462
506
Total current liabilities
1,609
1,686
Long-term debt, net
4,100
4,099
Operating lease liabilities
192
191
Long-term environmental remediation
520
530
Deferred income taxes
40
37
Other liabilities
590
588
Total liabilities
7,051
7,131
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized;
199,180,562 shares issued and 150,355,228 shares outstanding at March 31,
2026; 198,720,786 shares issued and 149,893,993 shares outstanding at
December 31, 2025)
2
2
Treasury stock, at cost (48,825,334 shares at March 31, 2026 and 48,826,793 at
December 31, 2025)
(1,802)
(1,802)
Additional paid-in capital
1,081
1,074
Retained earnings
1,178
1,220
Accumulated other comprehensive loss
(244)
(244)
Total Chemours stockholders' equity
215
250
Non-controlling interests
1
1
Total equity
216
251
Total liabilities and equity
$
7,267
$
7,382
The Chemours Company
Consolidated Statements of Cash Flows (Unaudited)1
(Dollars in millions)
Three Months Ended March 31,
2026
2025
Cash flows from operating activities
Net loss
$
(29)
$
(5)
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization
79
88
Loss (gain) on sales of assets and businesses
—
(1)
Equity in earnings of affiliates, net
(6)
(7)
Loss on extinguishment of debt
9
—
Amortization of debt issuance costs and issue discounts
3
3
Deferred tax benefit
(11)
(14)
Asset-related charges
1
1
Stock-based compensation expense
7
5
Net periodic pension cost (income)
—
—
Defined benefit plan contributions
(1)
(4)
Other operating charges and credits, net
(14)
37
Decrease (increase) in operating assets:
Accounts and notes receivable, net
(77)
(111)
Inventories and other current operating assets
32
(51)
Other non-current operating assets
17
48
(Decrease) increase in operating liabilities:
Accounts payable
(58)
(105)
Other current operating liabilities
12
(5)
Other non-current operating liabilities
(8)
9
Cash used for operating activities
(44)
(112)
Cash flows from investing activities
Purchases of property, plant, and equipment
(49)
(84)
Proceeds from life insurance policies
1
—
Proceeds from sales of assets and businesses
7
—
Foreign exchange contract settlements, net
(3)
(2)
Cash used for investing activities
(44)
(86)
Cash flows from financing activities
Proceeds from issuance of debt
700
—
Debt repayments
(689)
(8)
Payments on finance leases
(3)
(3)
Payments of debt issuance cost
(10)
—
Proceeds from supplier financing program
16
27
Payments to supplier financing program
(14)
(35)
Proceeds from exercised stock options, net
2
—
Payments related to tax withholdings on vested stock awards
(2)
(1)
Payments of dividends to the Company's common shareholders
(13)
(37)
Debt extinguishment payments
(6)
—
Cash used for financing activities
(19)
(57)
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash
equivalents
(2)
6
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents
(109)
(249)
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,
724
763
Cash, cash equivalents, restricted cash and restricted cash equivalents at March 31,
$
615
$
514
Supplemental cash flows information
Non-cash investing and financing activities:
Purchases of property, plant, and equipment included in accounts payable
$
27
$
26
The Chemours Company
Segment Financial and Operating Data (Unaudited)
(Dollars in millions)
Segment Net Sales1
Three Months
Ended
Sequential
Three Months Ended March 31,
Increase /
December 31,
Increase /
2026
2025
(Decrease)
2025
(Decrease)
Thermal & Specialized Solutions
$
568
$
466
$
102
$
444
$
124
Titanium Technologies
559
597
(38)
561
(2)
Advanced Performance
Materials
243
294
(51)
312
(69)
Other Non-Reportable Segment
11
11
0
12
(1)
Total Net Sales
$
1,381
$
1,368
$
13
$
1,329
$
52
Segment Adjusted EBITDA1
Three Months
Ended
Sequential
Three Months Ended March 31,
Increase /
December 31,
Increase /
2026
2025
(Decrease)
2025
(Decrease)
Thermal & Specialized Solutions
$
190
$
141
$
49
$
128
$
62
Titanium Technologies
$
18
$
50
$
(32)
$
23
$
(5)
Advanced Performance
Materials
$
5
$
32
$
(27)
$
12
$
(7)
Other Non-Reportable Segment
$
3
$
1
$
2
$
1
$
2
Quarterly Change in Net Sales from the three months ended March 31, 2025
March 31, 2026
Percentage Change
vs.
Percentage Change Due To
Net Sales
March 31, 2025
Price
Volume
Currency
Portfolio
Total Company
$
1,381
1
%
2
%
(4)
%
3
%
—
%
Thermal & Specialized Solutions
$
568
22
%
11
%
9
%
2
%
—
%
Titanium Technologies
559
(6)
%
(2)
%
(7)
%
3
%
—
%
Advanced Performance
Materials
243
(17)
%
(1)
%
(19)
%
3
%
—
%
Other Non-Reportable Segment
11
—
%
(2)
%
2
%
—
%
—
%
Quarterly Change in Net Sales from the three months ended December 31, 2025
March 31, 2026
Percentage Change
vs.
Percentage Change Due To
Net Sales
December 31, 2025
Price
Volume
Currency
Portfolio
Total Company
$
1,381
4
%
3
%
1
%
—
%
—
%
Thermal & Specialized Solutions
$
568
28
%
6
%
22
%
—
%
—
%
Titanium Technologies
559
—
%
3
%
(3)
%
—
%
—
%
Advanced Performance
Materials
243
(22)
%
—
%
(22)
%
—
%
—
%
Other Non-Reportable Segment
11
(2)
%
5
%
(7)
%
—
%
—
%
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)
GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation1
Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
Three Months Ended
Twelve Months Ended
March 31,
December 31,
March 31,
2026
2025
2025
2026
2025
(Loss) income before income taxes
$
(22)
$
—
$
(67)
$
(299)
$
38
Net (loss) income attributable to Chemours
$
(29)
$
(5)
$
(47)
$
(409)
$
12
Non-operating pension and other post-retirement
employee benefit (income) cost
(2)
(2)
(3)
(11)
(5)
Exchange (gains) losses, net
(1)
3
4
8
13
Restructuring, asset-related, and other charges (1)
13
32
4
39
85
Goodwill impairment charge (2)
—
—
—
—
56
Loss (gain) on extinguishment of debt (3)
9
—
5
14
1
Gain on sales of assets and businesses, net (4)
—
(1)
—
(7)
(1)
Transaction costs (5)
2
—
4
8
2
Qualified spend recovery (6)
(5)
(9)
(7)
(38)
(28)
Litigation-related charges (7)
20
—
19
340
2
Environmental charges (8)
7
—
20
100
15
Adjustments made to income taxes (9)
1
1
19
181
9
(Benefit from) provision for income taxes relating to
reconciling items (10)
(7)
—
(11)
(92)
(9)
Adjusted Net Income
8
19
7
133
152
Net income attributable to non-controlling interests
—
—
(1)
—
—
Interest expense, net
69
66
68
272
267
Depreciation and amortization (11)
79
77
81
319
299
All remaining provision for income taxes (10)
13
4
(27)
22
25
Adjusted EBITDA
$
169
$
166
$
128
$
746
$
743
Total debt principal
$
4,183
$
4,147
Less: Cash and cash equivalents
(563)
(464)
Total debt principal, net
$
3,620
$
3,683
Net Leverage Ratio (calculated using GAAP
earnings) (12)
(12.1)x
96.9x
Net Leverage Ratio (calculated using Non-GAAP
earnings) (12)
4.9x
5x
GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)1
(1)
For the twelve months ended March 31, 2026, restructuring, asset-related and other charges primarily includes employee separation charges related to the 2026 Restructuring Program as well as charges related to our decision to exit our SPS CapstoneTM business. For the twelve months ended March 31, 2025, restructuring, asset-related and other charges primarily include charges related to our decision to exit our SPS CapstoneTM business and the 2024 Restructuring Program. See "Note 4 –Restructuring, Asset-Related and Other Charges" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.
(2)
For the twelve months ended March 31, 2025, this represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2025.
(3)
For the twelve months ended March 31, 2026, loss on extinguishments of debt reflects costs associated with early redemption of the 2027 senior unsecured notes and partial early redemption of our 2028 senior unsecured notes during the first quarter of 2026. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.
(4)
For the twelve months ended March 31, 2026, gain on sales of assets and businesses, net includes a gain on sale of $7 million related to certain parcels of land at the Company's manufacturing site in Kuan Yin, Taiwan.
(5)
For the twelve months ended March 31, 2025, transaction costs include $4 million of costs associated with the Senior Secured Credit Facilities. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.
(6)
Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
(7)
Litigation-related charges pertain to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended March 31, 2026, litigation-related charges primarily includes $266 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $12 million in third-party legal fees directly related to the New Jersey Settlement agreement, $14 million related to the Company's portion of Chemours, DuPont, Corteva, EID's settlement agreement to resolve the Hoosick Falls class action lawsuit, $15 million related to alleged violations and discharge exceedances and $18 million related to reserves for asbestos and production liability matters. For the twelve months ended March 31, 2025, litigation-related charges include a $29 million accrual associated with the Ohio MDL and $27 million of benefits from insurance recoveries. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.
(8)
Environmental charges pertain to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended March 31, 2026, environmental charges primarily include changes to remediation reserves at the four sites covered by the New Jersey settlement agreement. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.
(9)
Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.
(10)
The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.
(11)
For the twelve months ended March 31, 2026 and March 31, 2025, accelerated depreciation charges of $12 million and $11 million, respectively, incurred as part of our decision to exit our SPS CapstoneTM business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.
(12)
Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by income (loss) before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation1
Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which include unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.
Three Months Ended
March 31,
December 31,
2026
2025
2025
Numerator:
Net (loss) income attributable to Chemours
$
(29)
$
(5)
$
(47)
Adjusted Net Income
8
19
7
Denominator:
Weighted-average number of common shares outstanding -
basic
150,767,077
149,918,386
150,464,150
Dilutive effect of the Company's employee compensation plans
(1)
819,728
491,194
398,511
Weighted-average number of common shares outstanding -
diluted (1)
151,586,805
150,409,579
150,862,661
Basic (loss) earnings per share of common stock (2)
$
(0.19)
$
(0.03)
$
(0.31)
Diluted (loss) earnings per share of common stock (1) (2)
(0.19)
(0.03)
(0.31)
Adjusted basic earnings per share of common stock (2)
0.05
0.13
0.05
Adjusted diluted earnings per share of common stock (1) (2)
0.05
0.13
0.05
(1)
In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended March 31, 2026, three months ended March 31, 2025 and the three months ended December 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended March 31, 2026, three months ended March 31, 2025 and the three months ended December 31, 2025 as Adjusted Net Income was in a net income position.
(2)
Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.
GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation
Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
Three Months Ended
March 31,
December 31,
2026
2025
2025
Cash flows (used for) provided by operating activities
$
(44)
$
(112)
$
137
Less: Purchases of property, plant, and equipment
(49)
(84)
(45)
Free Cash Flows
$
(93)
$
(196)
$
92
Adjusted EBITDA
169
166
128
Free Cash Flow Conversion
(55)
%
(118)
%
72
%
2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation (1)
Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.
Estimated
Year Ended December 31, 2026
Low
High
Cash flows provided by (used for) operating activities
$
445
$
565
Less: Purchases of property, plant, and equipment
(275)
(325)
Free Cash Flows
$
170
$
240
Adjusted EBITDA
800
900
Free Cash Flow Conversion
21
%
27
%
(1)
Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site.
The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)
2026 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)
(Estimated)
Year Ending December 31, 2026
Low
High
Net income attributable to Chemours
$
165
$
225
Restructuring, transaction, and other costs, net (2)
(35)
(45)
Adjusted Net Income
130
180
Interest expense, net
275
285
Depreciation and amortization
315
325
All remaining provision for income taxes
80
110
Adjusted EBITDA
$
800
$
900
(1)
The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.
(2)
Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.
Alta Fundamental Advisers LLC cut its stake in Chemours (CC +3.07%) by 175,000 shares during the first quarter, an estimated $3.05 million trade based on quarterly average pricing, according to an SEC filing dated May 5, 2026,.
Sold 175,000 shares of ChemoursQuarter-end position value decreased by $5.1 million, reflecting both trading and stock price changes over the periodPost-trade stake: 700,000 shares, valued at $15.42 millionChemours now accounts for 5.8% of the fund’s AUM, making it the fund’s fifth largest holdingWhat else to knowTop holdings after the filing:NYSE: TDAY: $75.8 million (28.6% of AUM)NASDAQ: LILAK: $27.4 million (10.3% of AUM)NYSE: PUMP: $25.6 million (9.6% of AUM)NYSE: BTU: $16.5 million (6.2% of AUM)NYSE: CC: $15.4 million (5.8% of AUM)Company OverviewMetricValueRevenue (TTM)$5.8 billionNet Loss (TTM)($386.00 million)Dividend Yield1.3%Price (as of market close May 4)$27.22Company SnapshotChemours is a global provider of performance chemicals, with a portfolio spanning titanium technologies, thermal and specialized solutions, advanced performance materials, and chemical solutions. The company supplies essential materials for a wide range of industrial and consumer applications.
Provides titanium dioxide pigments, refrigerants, advanced performance materials, and industrial chemicals across global markets.Serves a diverse customer base, including manufacturers, resellers, and distributors in sectors such as coatings, plastics, electronics, and energy.Generates revenue by manufacturing and distributing specialty chemicals for industrial, packaging, coatings, electronics, and automotive applications.What this transaction means for investorsAlta Fundamental sold 20% of its Chemours shares during the first quarter. It still holds 700,000 shares valued at $15.4 million, and the position still represents 5.8% of its $265.3 million in reported AUM.
The investment firm sold stock as the shares rallied over the last few months. This year, through May 4, Chemours shares have gained an eye-popping 136%. That trounced the S&P 500 index’s 6.2%.
Chemours reported $5.8 billion in sales in 2025, flat versus 2024. Earlier this year, management stated that it expects 3% to 5% growth this year. With first-quarter sales increasing 1% year over year to $1.4 billion, the pace will need to pick up to meet these expectations.
Investors should tread carefully. After all, last year the board of directors slashed the company’s quarterly dividends from $0.25 a share to $0.0875 a share. It’s not usually a good sign when companies cut dividends, especially so sharply.
Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool recommends USA Today. The Motley Fool has a disclosure policy.
For the quarter ended March 2026, Chemours (CC - Free Report) reported revenue of $1.38 billion, up 1% over the same period last year. EPS came in at $0.05, compared to $0.13 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.4 billion, representing a surprise of -1.54%. The company delivered an EPS surprise of +195.24%, with the consensus EPS estimate being -$0.05.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Other Segment: $11 million compared to the $10.78 million average estimate based on three analysts. The reported number represents a change of 0% year over year.Revenues- Titanium Technologies: $559 million compared to the $544.35 million average estimate based on three analysts. The reported number represents a change of -6.4% year over year.Revenues- Advanced Performance Materials: $243 million versus $257.39 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -17.4% change.Revenues- Thermal & Specialized Solutions: $568 million compared to the $565.65 million average estimate based on three analysts. The reported number represents a change of +21.9% year over year.Adjusted EBITDA- Titanium Technologies: $18 million compared to the $3.21 million average estimate based on three analysts.Adjusted EBITDA- Other Segment: $3 million compared to the $1.18 million average estimate based on three analysts.Adjusted EBITDA- Advanced Performance Materials: $5 million versus the three-analyst average estimate of $3.69 million.Adjusted EBITDA- Thermal & Specialized Solutions: $190 million versus $176.61 million estimated by three analysts on average.View all Key Company Metrics for Chemours here>>>
Shares of Chemours have returned +25.4% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
, /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC) today announced that the Board of Directors of Chemours declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the second quarter of 2026. The dividend will be paid on June 16, 2026, to stockholders of record as of the close of business on May 17, 2026.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
Key Takeaways Chemours posted a wider Q1 loss as lower volumes weighed on key business segments. CC expects Q2 net sales to rise 15-20% sequentially on favorable seasonal trends. CC maintained its 2026 outlook for 3-5% sales growth and $800-$900M adjusted EBITDA. The Chemours Company (CC - Free Report) reported a net loss of $29 million or 19 cents per share for the first quarter of 2026. This compares unfavorably with the year-ago quarter’s net loss of $5 million or 3 cents per share.
Barring one-time items, earnings were 5 cents per share, which topped the Zacks Consensus Estimate of a loss of 5 cents.
The company reported first-quarter net sales of $1,381 million, reflecting a 1% increase from the previous-year quarter. However, the figure missed the Zacks Consensus Estimate of $1,402.6 million. Net sales were primarily aided by a 2% increase in price and a 3% favorable currency impact, partly offset by a 4% decrease in volumes.
Adjusted EBITDA rose 2% year over year to $169 million for the quarter. The increase was driven by higher pricing, favorable currency and other income, which more than offset higher costs and lower sales volumes in the Advanced Performance Materials and Titanium Technologies segments.
The Chemours Company Price, Consensus and EPS SurpriseCC’s Segment HighlightsThe Titanium Technologies division recorded revenues of $559 million in the first quarter, marking a 6% decrease from the previous year. The figure beat our estimate of $543.3 million. This downside was primarily due to a 7% decline in volumes globally and a 2% decrease in pricing, partly offset by a 3% favorable currency impact.
In the Thermal & Specialized Solutions segment, revenues saw a 22% year-over-year increase, reaching $568 million in the reported quarter. The figure was almost in line with our estimate of $568.3 million. Net sales growth was mainly driven by an 11% increase in price and a 9% rise in volume, with a 2% currency tailwind. Increased pricing was primarily driven by automotive Freon Refrigerant sales in North America.
Volume growth was supported by the continued transition to Opteon Refrigerants as well as automotive Freon Refrigerant sales in North America.
Revenues in the Advanced Performance Materials unit amounted to $243 million, which declined 17% year over year. The figure missed our estimate of $256.5 million. The downside was mainly caused by a 19% decrease in volume and a 1% decline in price, partly offset by a 3% favorable currency impact. The volume decline was primarily due to sales constraints from the Washington Works plant outage in the first quarter and the closure of the Advanced Materials SPS Capstone line, completed in the third quarter of 2025.
CC’s FinancialsOperating cash usage in the first quarter was $44 million compared with $112 million in the year-ago quarter, reflecting improvements in net working capital performance. Capital expenditures were $49 million compared with $84 million in the prior-year quarter. Free cash flow reflected a usage of $93 million compared with $196 million in the first quarter of 2025.
As of March 31, 2026, Chemours had consolidated gross debt of $4.2 billion. Debt, net of $563 million in unrestricted cash and cash equivalents, was $3.6 billion. Total liquidity was $1.5 billion.
CC’s Q2 & 2026 OutlookFor the second quarter, the company expects consolidated net sales to increase in the range of 15-20% sequentially, driven by favorable seasonal trends. Consolidated adjusted EBITDA is expected to be in the range of $220-$250 million. Corporate expenses are expected to be roughly $45-$50 million. The company also expects capital expenditures of around $50 million and free cash flow of at least $100 million.
CC expects Thermal & Specialized Solutions’ net sales to increase sequentially in the low-to-mid-teens percentage range in the second quarter. Adjusted EBITDA is projected to be between $210 million and $225 million.
Titanium Technologies’ net sales are expected to increase sequentially in the mid-to-high-teens percentage range, driven by seasonal volume strength and a favorable mix for TiO2 pigment. Adjusted EBITDA is expected to be in the range of $40-$50 million.
Advanced Performance Materials’ net sales are expected to rise sequentially in the low-to-high-thirties percentage range, driven by a return to normal operating levels at the Washington Works facility. Adjusted EBITDA for APM is expected to be between $12 million and $18 million.
For 2026, Chemours continues to expect net sales to grow in the range of 3-5% year over year. Adjusted EBITDA is projected in the range of $800-$900 million. Capital expenditures are expected in the range of $275-$325 million, with free cash flow conversion above 20%.
CC’s Price PerformanceCC shares have surged 117.1% in the past year compared with an 25.1% rise in the industry.
Image Source: Zacks Investment Research
CC’s Zacks Rank & Key PicksCC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth a look in the basic materials space are Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) , Idaho Strategic Resources, Inc. (IDR - Free Report) and Hawkins, Inc. (HWKN - Free Report) .
Sociedad is slated to report first-quarter 2026 results on May 26. The Zacks Consensus Estimate for loss is pegged at $1.36 per share, indicating 183.3% year-over-year growth. SQM carries a Zacks Rank #2 (Buy) at present.
Idaho is expected to report first-quarter 2026 results on May 14. The Zacks Consensus Estimate for earnings is pegged at 43 cents per share, indicating 258.3% year-over-year growth. IDR sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hawkins is scheduled to report fiscal fourth-quarter results on May 13. The Zacks Consensus Estimate for HWKN’s fourth-quarter earnings is pegged at 77 cents per share. HWKN currently has a Zacks Rank #2.
